{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "4b6eb145",
   "metadata": {},
   "source": [
    "# MDR parser: How it works"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "d0fe4d6a",
   "metadata": {},
   "outputs": [],
   "source": [
    "from pathlib import Path\n",
    "from bs4 import BeautifulSoup\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "de9eacd9",
   "metadata": {},
   "source": [
    "## Function explained\n",
    "\n",
    "`def parse_mdr(html_file: Path, lang: str = \"EN\") -> Tuple[List[Dict], List[Dict]]:`\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "27d96cff",
   "metadata": {},
   "source": [
    "### Opening and access the HTML data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "8a3c7032",
   "metadata": {},
   "outputs": [],
   "source": [
    "# For opening the raw HTML file we declare the path here as a class.\n",
    "html_file = Path(\"../data/regulations/32017R0745/EN/raw/raw.html\")\n",
    "\n",
    "# Then we read the content of the file into a variable.\n",
    "raw_html = html_file.read_text(encoding=\"utf-8\")\n",
    "\n",
    "# We parse the raw HTML content using BeautifulSoup to create a navigable tree structure.\n",
    "soup = BeautifulSoup(raw_html, \"lxml\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3316557a",
   "metadata": {},
   "source": [
    "Up to now we have just used the `Path` class from the library `Pathlib` to create a path object, which then we used to open the `raw_html` through the `read_text()` method. Then the `soup` variable was created which contains a navigable tree structure thanks to html tagged structure. Printing the `soup` variable will output the full html mess "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "8cdc975e",
   "metadata": {},
   "outputs": [],
   "source": [
    "blocks = soup.find_all([\"p\", \"table\", \"h1\", \"h2\", \"h3\", \"h4\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "b98269f8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"10%\"/>\n",
       " <col width=\"10%\"/>\n",
       " <col width=\"60%\"/>\n",
       " <col width=\"20%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td>\n",
       " <p class=\"oj-hd-date\">5.5.2017   </p>\n",
       " </td>\n",
       " <td>\n",
       " <p class=\"oj-hd-lg\">EN</p>\n",
       " </td>\n",
       " <td>\n",
       " <p class=\"oj-hd-ti\">Official Journal of the European Union</p>\n",
       " </td>\n",
       " <td>\n",
       " <p class=\"oj-hd-oj\">L 117/1</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-hd-date\">5.5.2017   </p>,\n",
       " <p class=\"oj-hd-lg\">EN</p>,\n",
       " <p class=\"oj-hd-ti\">Official Journal of the European Union</p>,\n",
       " <p class=\"oj-hd-oj\">L 117/1</p>,\n",
       " <p class=\"oj-doc-ti\" id=\"d1e40-1-1\">\n",
       "             REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL\n",
       "          </p>,\n",
       " <p class=\"oj-doc-ti\">of 5 April 2017\n",
       "          </p>,\n",
       " <p class=\"oj-doc-ti\">on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC</p>,\n",
       " <p class=\"oj-doc-ti\">(Text with EEA relevance)</p>,\n",
       " <p class=\"oj-normal\">THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,</p>,\n",
       " <p class=\"oj-normal\">Having regard to the Treaty on the Functioning of the European Union, and in particular Article 114 and Article 168(4)(c) thereof,</p>,\n",
       " <p class=\"oj-normal\">Having regard to the proposal from the European Commission,</p>,\n",
       " <p class=\"oj-normal\">After transmission of the draft legislative act to the national parliaments,</p>,\n",
       " <p class=\"oj-normal\">Having regard to the opinion of the European Economic and Social Committee <a href=\"#ntr1-L_2017117EN.01000101-E0001\" id=\"ntc1-L_2017117EN.01000101-E0001\">(<span class=\"oj-super oj-note-tag\">1</span>)</a>,</p>,\n",
       " <p class=\"oj-normal\">After consulting the Committee of the Regions,</p>,\n",
       " <p class=\"oj-normal\">Acting in accordance with the ordinary legislative procedure <a href=\"#ntr2-L_2017117EN.01000101-E0002\" id=\"ntc2-L_2017117EN.01000101-E0002\">(<span class=\"oj-super oj-note-tag\">2</span>)</a>,</p>,\n",
       " <p class=\"oj-normal\">Whereas:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(1)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Council Directive 90/385/EEC <a href=\"#ntr3-L_2017117EN.01000101-E0003\" id=\"ntc3-L_2017117EN.01000101-E0003\">(<span class=\"oj-super oj-note-tag\">3</span>)</a> and Council Directive 93/42/EEC <a href=\"#ntr4-L_2017117EN.01000101-E0004\" id=\"ntc4-L_2017117EN.01000101-E0004\">(<span class=\"oj-super oj-note-tag\">4</span>)</a> constitute the Union regulatory framework for medical devices, other than <span class=\"oj-italic\">in vitro</span> diagnostic medical devices. However, a fundamental revision of those Directives is needed to establish a robust, transparent, predictable and sustainable regulatory framework for medical devices which ensures a high level of safety and health whilst supporting innovation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(1)</p>,\n",
       " <p class=\"oj-normal\">Council Directive 90/385/EEC <a href=\"#ntr3-L_2017117EN.01000101-E0003\" id=\"ntc3-L_2017117EN.01000101-E0003\">(<span class=\"oj-super oj-note-tag\">3</span>)</a> and Council Directive 93/42/EEC <a href=\"#ntr4-L_2017117EN.01000101-E0004\" id=\"ntc4-L_2017117EN.01000101-E0004\">(<span class=\"oj-super oj-note-tag\">4</span>)</a> constitute the Union regulatory framework for medical devices, other than <span class=\"oj-italic\">in vitro</span> diagnostic medical devices. However, a fundamental revision of those Directives is needed to establish a robust, transparent, predictable and sustainable regulatory framework for medical devices which ensures a high level of safety and health whilst supporting innovation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(2)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">This Regulation aims to ensure the smooth functioning of the internal market as regards medical devices, taking as a base a high level of protection of health for patients and users, and taking into account the small- and medium-sized enterprises that are active in this sector. At the same time, this Regulation sets high standards of quality and safety for medical devices in order to meet common safety concerns as regards such products. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 of the Treaty on the Functioning of the European Union (TFEU), this Regulation harmonises the rules for the placing on the market and putting into service of medical devices and their accessories on the Union market thus allowing them to benefit from the principle of free movement of goods. As regards Article 168(4)(c) TFEU, this Regulation sets high standards of quality and safety for medical devices by ensuring, among other things, that data generated in clinical investigations are reliable and robust and that the safety of the subjects participating in a clinical investigation is protected.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(2)</p>,\n",
       " <p class=\"oj-normal\">This Regulation aims to ensure the smooth functioning of the internal market as regards medical devices, taking as a base a high level of protection of health for patients and users, and taking into account the small- and medium-sized enterprises that are active in this sector. At the same time, this Regulation sets high standards of quality and safety for medical devices in order to meet common safety concerns as regards such products. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 of the Treaty on the Functioning of the European Union (TFEU), this Regulation harmonises the rules for the placing on the market and putting into service of medical devices and their accessories on the Union market thus allowing them to benefit from the principle of free movement of goods. As regards Article 168(4)(c) TFEU, this Regulation sets high standards of quality and safety for medical devices by ensuring, among other things, that data generated in clinical investigations are reliable and robust and that the safety of the subjects participating in a clinical investigation is protected.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(3)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">This Regulation does not seek to harmonise rules relating to the further making available on the market of medical devices after they have already been put into service such as in the context of second-hand sales.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(3)</p>,\n",
       " <p class=\"oj-normal\">This Regulation does not seek to harmonise rules relating to the further making available on the market of medical devices after they have already been put into service such as in the context of second-hand sales.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(4)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Key elements of the existing regulatory approach, such as the supervision of notified bodies, conformity assessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding medical devices should be introduced, to improve health and safety.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(4)</p>,\n",
       " <p class=\"oj-normal\">Key elements of the existing regulatory approach, such as the supervision of notified bodies, conformity assessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding medical devices should be introduced, to improve health and safety.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(5)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">To the extent possible, guidance developed for medical devices at international level, in particular in the context of the Global Harmonization Task Force (GHTF) and its follow-up initiative, the International Medical Devices Regulators Forum (IMDRF), should be taken into account to promote the global convergence of regulations which contributes to a high level of safety protection worldwide, and to facilitate trade, in particular in the provisions on Unique Device Identification, general safety and performance requirements, technical documentation, classification rules, conformity assessment procedures and clinical investigations.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(5)</p>,\n",
       " <p class=\"oj-normal\">To the extent possible, guidance developed for medical devices at international level, in particular in the context of the Global Harmonization Task Force (GHTF) and its follow-up initiative, the International Medical Devices Regulators Forum (IMDRF), should be taken into account to promote the global convergence of regulations which contributes to a high level of safety protection worldwide, and to facilitate trade, in particular in the provisions on Unique Device Identification, general safety and performance requirements, technical documentation, classification rules, conformity assessment procedures and clinical investigations.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(6)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">For historical reasons, active implantable medical devices, covered by Directive 90/385/EEC, and other medical devices, covered by Directive 93/42/EEC, were regulated in two separate legal instruments. In the interest of simplification, both directives, which have been amended several times, should be replaced by a single legislative act applicable to all medical devices other than <span class=\"oj-italic\">in vitro</span> diagnostic medical devices.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(6)</p>,\n",
       " <p class=\"oj-normal\">For historical reasons, active implantable medical devices, covered by Directive 90/385/EEC, and other medical devices, covered by Directive 93/42/EEC, were regulated in two separate legal instruments. In the interest of simplification, both directives, which have been amended several times, should be replaced by a single legislative act applicable to all medical devices other than <span class=\"oj-italic\">in vitro</span> diagnostic medical devices.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(7)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The scope of application of this Regulation should be clearly delimited from other Union harmonisation legislation concerning products, such as <span class=\"oj-italic\">in vitro</span> diagnostic medical devices, medicinal products, cosmetics and food. Therefore, Regulation (EC) No 178/2002 of the European Parliament and of the Council <a href=\"#ntr5-L_2017117EN.01000101-E0005\" id=\"ntc5-L_2017117EN.01000101-E0005\">(<span class=\"oj-super oj-note-tag\">5</span>)</a> should be amended to exclude medical devices from its scope.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(7)</p>,\n",
       " <p class=\"oj-normal\">The scope of application of this Regulation should be clearly delimited from other Union harmonisation legislation concerning products, such as <span class=\"oj-italic\">in vitro</span> diagnostic medical devices, medicinal products, cosmetics and food. Therefore, Regulation (EC) No 178/2002 of the European Parliament and of the Council <a href=\"#ntr5-L_2017117EN.01000101-E0005\" id=\"ntc5-L_2017117EN.01000101-E0005\">(<span class=\"oj-super oj-note-tag\">5</span>)</a> should be amended to exclude medical devices from its scope.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(8)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">It should be the responsibility of the Member States to decide on a case-by-case basis whether or not a product falls within the scope of this Regulation. In order to ensure consistent qualification decisions in that regard across all Member States, particularly with regard to borderline cases, the Commission should be allowed to, on its own initiative or at the duly substantiated request of a Member State, having consulted the Medical Device Coordination Group (‘MDCG’), decide on a case-by-case basis whether or not a specific product, category or group of products falls within the scope of this Regulation. When deliberating on the regulatory status of products in borderline cases involving medicinal products, human tissues and cells, biocidal products or food products, the Commission should ensure an appropriate level of consultation of the European Medicines Agency (EMA), the European Chemicals Agency and the European Food Safety Authority, as relevant.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(8)</p>,\n",
       " <p class=\"oj-normal\">It should be the responsibility of the Member States to decide on a case-by-case basis whether or not a product falls within the scope of this Regulation. In order to ensure consistent qualification decisions in that regard across all Member States, particularly with regard to borderline cases, the Commission should be allowed to, on its own initiative or at the duly substantiated request of a Member State, having consulted the Medical Device Coordination Group (‘MDCG’), decide on a case-by-case basis whether or not a specific product, category or group of products falls within the scope of this Regulation. When deliberating on the regulatory status of products in borderline cases involving medicinal products, human tissues and cells, biocidal products or food products, the Commission should ensure an appropriate level of consultation of the European Medicines Agency (EMA), the European Chemicals Agency and the European Food Safety Authority, as relevant.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(9)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Since in some cases it is difficult to distinguish between medical devices and cosmetic products, the possibility of taking a Union-wide decision regarding the regulatory status of a product should also be introduced in Regulation (EC) No 1223/2009 of the European Parliament and of the Council <a href=\"#ntr6-L_2017117EN.01000101-E0006\" id=\"ntc6-L_2017117EN.01000101-E0006\">(<span class=\"oj-super oj-note-tag\">6</span>)</a>.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(9)</p>,\n",
       " <p class=\"oj-normal\">Since in some cases it is difficult to distinguish between medical devices and cosmetic products, the possibility of taking a Union-wide decision regarding the regulatory status of a product should also be introduced in Regulation (EC) No 1223/2009 of the European Parliament and of the Council <a href=\"#ntr6-L_2017117EN.01000101-E0006\" id=\"ntc6-L_2017117EN.01000101-E0006\">(<span class=\"oj-super oj-note-tag\">6</span>)</a>.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(10)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Products which combine a medicinal product or substance and a medical device are regulated either under this Regulation or under Directive 2001/83/EC of the European Parliament and of the Council. <a href=\"#ntr7-L_2017117EN.01000101-E0007\" id=\"ntc7-L_2017117EN.01000101-E0007\">(<span class=\"oj-super oj-note-tag\">7</span>)</a> The two legislative acts should ensure appropriate interaction in terms of consultations during pre-market assessment, and of exchange of information in the context of vigilance activities involving such combination products. For medicinal products that integrate a medical device part, compliance with the general safety and performance requirements laid down in this Regulation for the device part should be adequately assessed in the context of the marketing authorisation for such medicinal products. Directive 2001/83/EC should therefore be amended.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(10)</p>,\n",
       " <p class=\"oj-normal\">Products which combine a medicinal product or substance and a medical device are regulated either under this Regulation or under Directive 2001/83/EC of the European Parliament and of the Council. <a href=\"#ntr7-L_2017117EN.01000101-E0007\" id=\"ntc7-L_2017117EN.01000101-E0007\">(<span class=\"oj-super oj-note-tag\">7</span>)</a> The two legislative acts should ensure appropriate interaction in terms of consultations during pre-market assessment, and of exchange of information in the context of vigilance activities involving such combination products. For medicinal products that integrate a medical device part, compliance with the general safety and performance requirements laid down in this Regulation for the device part should be adequately assessed in the context of the marketing authorisation for such medicinal products. Directive 2001/83/EC should therefore be amended.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(11)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Union legislation, in particular Regulation (EC) No 1394/2007 of the European Parliament and of the Council <a href=\"#ntr8-L_2017117EN.01000101-E0008\" id=\"ntc8-L_2017117EN.01000101-E0008\">(<span class=\"oj-super oj-note-tag\">8</span>)</a> and Directive 2004/23/EC of the European Parliament and of the Council <a href=\"#ntr9-L_2017117EN.01000101-E0009\" id=\"ntc9-L_2017117EN.01000101-E0009\">(<span class=\"oj-super oj-note-tag\">9</span>)</a>, is incomplete in respect of certain products manufactured utilising derivatives of tissues or cells of human origin that are non-viable or are rendered non-viable. Such products should come under the scope of this Regulation, provided they comply with the definition of a medical device or are covered by this Regulation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(11)</p>,\n",
       " <p class=\"oj-normal\">Union legislation, in particular Regulation (EC) No 1394/2007 of the European Parliament and of the Council <a href=\"#ntr8-L_2017117EN.01000101-E0008\" id=\"ntc8-L_2017117EN.01000101-E0008\">(<span class=\"oj-super oj-note-tag\">8</span>)</a> and Directive 2004/23/EC of the European Parliament and of the Council <a href=\"#ntr9-L_2017117EN.01000101-E0009\" id=\"ntc9-L_2017117EN.01000101-E0009\">(<span class=\"oj-super oj-note-tag\">9</span>)</a>, is incomplete in respect of certain products manufactured utilising derivatives of tissues or cells of human origin that are non-viable or are rendered non-viable. Such products should come under the scope of this Regulation, provided they comply with the definition of a medical device or are covered by this Regulation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(12)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Certain groups of products for which a manufacturer claims only an aesthetic or another non-medical purpose but which are similar to medical devices in terms of functioning and risks profile should be covered by this Regulation. In order for manufacturers to be able to demonstrate the conformity of such products, the Commission should adopt common specifications at least with regard to application of risk management and, where necessary, clinical evaluation regarding safety. Such common specifications should be developed specifically for a group of products without an intended medical purpose and should not be used for conformity assessment of the analogous devices with a medical purpose. Devices with both a medical and a non-medical intended purpose should fulfil both the requirements applicable to devices with, and to devices without, an intended medical purpose.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(12)</p>,\n",
       " <p class=\"oj-normal\">Certain groups of products for which a manufacturer claims only an aesthetic or another non-medical purpose but which are similar to medical devices in terms of functioning and risks profile should be covered by this Regulation. In order for manufacturers to be able to demonstrate the conformity of such products, the Commission should adopt common specifications at least with regard to application of risk management and, where necessary, clinical evaluation regarding safety. Such common specifications should be developed specifically for a group of products without an intended medical purpose and should not be used for conformity assessment of the analogous devices with a medical purpose. Devices with both a medical and a non-medical intended purpose should fulfil both the requirements applicable to devices with, and to devices without, an intended medical purpose.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(13)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">As is the case for products that contain viable tissues or cells of human or animal origin, that are explicitly excluded from Directives 90/385/EEC and 93/42/EEC and hence from this Regulation, it should be clarified that products that contain or consist of viable biological materials or viable organisms of another origin in order to achieve or support the intended purpose of those products are not covered by this Regulation either.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(13)</p>,\n",
       " <p class=\"oj-normal\">As is the case for products that contain viable tissues or cells of human or animal origin, that are explicitly excluded from Directives 90/385/EEC and 93/42/EEC and hence from this Regulation, it should be clarified that products that contain or consist of viable biological materials or viable organisms of another origin in order to achieve or support the intended purpose of those products are not covered by this Regulation either.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(14)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The requirements laid down in Directive 2002/98/EC of the European Parliament and of the Council <a href=\"#ntr10-L_2017117EN.01000101-E0010\" id=\"ntc10-L_2017117EN.01000101-E0010\">(<span class=\"oj-super oj-note-tag\">10</span>)</a> should continue to apply.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(14)</p>,\n",
       " <p class=\"oj-normal\">The requirements laid down in Directive 2002/98/EC of the European Parliament and of the Council <a href=\"#ntr10-L_2017117EN.01000101-E0010\" id=\"ntc10-L_2017117EN.01000101-E0010\">(<span class=\"oj-super oj-note-tag\">10</span>)</a> should continue to apply.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(15)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">There is scientific uncertainty about the risks and benefits of nanomaterials used for devices. In order to ensure a high level of health protection, free movement of goods and legal certainty for manufacturers, it is necessary to introduce a uniform definition for nanomaterials based on Commission Recommendation 2011/696/EU <a href=\"#ntr11-L_2017117EN.01000101-E0011\" id=\"ntc11-L_2017117EN.01000101-E0011\">(<span class=\"oj-super oj-note-tag\">11</span>)</a>, with the necessary flexibility to adapt that definition to scientific and technical progress and subsequent regulatory development at Union and international level. In the design and manufacture of devices, manufacturers should take special care when using nanoparticles for which there is a high or medium potential for internal exposure. Such devices should be subject to the most stringent conformity assessment procedures. In preparation of implementing acts regulating the practical and uniform application of the corresponding requirements laid down in this Regulation, the relevant scientific opinions of the relevant scientific committees should be taken into account.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(15)</p>,\n",
       " <p class=\"oj-normal\">There is scientific uncertainty about the risks and benefits of nanomaterials used for devices. In order to ensure a high level of health protection, free movement of goods and legal certainty for manufacturers, it is necessary to introduce a uniform definition for nanomaterials based on Commission Recommendation 2011/696/EU <a href=\"#ntr11-L_2017117EN.01000101-E0011\" id=\"ntc11-L_2017117EN.01000101-E0011\">(<span class=\"oj-super oj-note-tag\">11</span>)</a>, with the necessary flexibility to adapt that definition to scientific and technical progress and subsequent regulatory development at Union and international level. In the design and manufacture of devices, manufacturers should take special care when using nanoparticles for which there is a high or medium potential for internal exposure. Such devices should be subject to the most stringent conformity assessment procedures. In preparation of implementing acts regulating the practical and uniform application of the corresponding requirements laid down in this Regulation, the relevant scientific opinions of the relevant scientific committees should be taken into account.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(16)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Safety aspects addressed by Directive 2014/30/EU of the European Parliament and of the Council <a href=\"#ntr12-L_2017117EN.01000101-E0012\" id=\"ntc12-L_2017117EN.01000101-E0012\">(<span class=\"oj-super oj-note-tag\">12</span>)</a> are an integral part of the general safety and performance requirements laid down in this Regulation for devices. Consequently, this Regulation should be considered a <span class=\"oj-italic\">lex specialis</span> in relation to that Directive.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(16)</p>,\n",
       " <p class=\"oj-normal\">Safety aspects addressed by Directive 2014/30/EU of the European Parliament and of the Council <a href=\"#ntr12-L_2017117EN.01000101-E0012\" id=\"ntc12-L_2017117EN.01000101-E0012\">(<span class=\"oj-super oj-note-tag\">12</span>)</a> are an integral part of the general safety and performance requirements laid down in this Regulation for devices. Consequently, this Regulation should be considered a <span class=\"oj-italic\">lex specialis</span> in relation to that Directive.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(17)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">This Regulation should include requirements regarding the design and manufacture of devices emitting ionizing radiation without affecting the application of Council Directive 2013/59/Euratom <a href=\"#ntr13-L_2017117EN.01000101-E0013\" id=\"ntc13-L_2017117EN.01000101-E0013\">(<span class=\"oj-super oj-note-tag\">13</span>)</a> which pursues other objectives.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(17)</p>,\n",
       " <p class=\"oj-normal\">This Regulation should include requirements regarding the design and manufacture of devices emitting ionizing radiation without affecting the application of Council Directive 2013/59/Euratom <a href=\"#ntr13-L_2017117EN.01000101-E0013\" id=\"ntc13-L_2017117EN.01000101-E0013\">(<span class=\"oj-super oj-note-tag\">13</span>)</a> which pursues other objectives.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(18)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">This Regulation should include requirements for devices' design, safety and performance characteristics which are developed in such a way as to prevent occupational injuries, including protection from radiation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(18)</p>,\n",
       " <p class=\"oj-normal\">This Regulation should include requirements for devices' design, safety and performance characteristics which are developed in such a way as to prevent occupational injuries, including protection from radiation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(19)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">It is necessary to clarify that software in its own right, when specifically intended by the manufacturer to be used for one or more of the medical purposes set out in the definition of a medical device, qualifies as a medical device, while software for general purposes, even when used in a healthcare setting, or software intended for life-style and well-being purposes is not a medical device. The qualification of software, either as a device or an accessory, is independent of the software's location or the type of interconnection between the software and a device.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(19)</p>,\n",
       " <p class=\"oj-normal\">It is necessary to clarify that software in its own right, when specifically intended by the manufacturer to be used for one or more of the medical purposes set out in the definition of a medical device, qualifies as a medical device, while software for general purposes, even when used in a healthcare setting, or software intended for life-style and well-being purposes is not a medical device. The qualification of software, either as a device or an accessory, is independent of the software's location or the type of interconnection between the software and a device.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(20)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The definitions in this Regulation, regarding devices themselves, the making available of devices, economic operators, users and specific processes, the conformity assessment, clinical investigations and clinical evaluations, post-market surveillance, vigilance and market surveillance, standards and other technical specifications, should be aligned with well-established practice in the field at Union and international level in order to enhance legal certainty.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(20)</p>,\n",
       " <p class=\"oj-normal\">The definitions in this Regulation, regarding devices themselves, the making available of devices, economic operators, users and specific processes, the conformity assessment, clinical investigations and clinical evaluations, post-market surveillance, vigilance and market surveillance, standards and other technical specifications, should be aligned with well-established practice in the field at Union and international level in order to enhance legal certainty.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(21)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">It should be made clear that it is essential that devices offered to persons in the Union by means of information society services within the meaning of Directive (EU) 2015/1535 of the European Parliament and of the Council <a href=\"#ntr14-L_2017117EN.01000101-E0014\" id=\"ntc14-L_2017117EN.01000101-E0014\">(<span class=\"oj-super oj-note-tag\">14</span>)</a> and devices used in the context of a commercial activity to provide a diagnostic or therapeutic service to persons within the Union comply with the requirements of this Regulation, where the product in question is placed on the market or the service is provided in the Union.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(21)</p>,\n",
       " <p class=\"oj-normal\">It should be made clear that it is essential that devices offered to persons in the Union by means of information society services within the meaning of Directive (EU) 2015/1535 of the European Parliament and of the Council <a href=\"#ntr14-L_2017117EN.01000101-E0014\" id=\"ntc14-L_2017117EN.01000101-E0014\">(<span class=\"oj-super oj-note-tag\">14</span>)</a> and devices used in the context of a commercial activity to provide a diagnostic or therapeutic service to persons within the Union comply with the requirements of this Regulation, where the product in question is placed on the market or the service is provided in the Union.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(22)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">To recognise the important role of standardisation in the field of medical devices, compliance with harmonised standards as defined in Regulation (EU) No 1025/2012 of the European Parliament and of the Council <a href=\"#ntr15-L_2017117EN.01000101-E0015\" id=\"ntc15-L_2017117EN.01000101-E0015\">(<span class=\"oj-super oj-note-tag\">15</span>)</a> should be a means for manufacturers to demonstrate conformity with the general safety and performance requirements and other legal requirements, such as those relating to quality and risk management, laid down in this Regulation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(22)</p>,\n",
       " <p class=\"oj-normal\">To recognise the important role of standardisation in the field of medical devices, compliance with harmonised standards as defined in Regulation (EU) No 1025/2012 of the European Parliament and of the Council <a href=\"#ntr15-L_2017117EN.01000101-E0015\" id=\"ntc15-L_2017117EN.01000101-E0015\">(<span class=\"oj-super oj-note-tag\">15</span>)</a> should be a means for manufacturers to demonstrate conformity with the general safety and performance requirements and other legal requirements, such as those relating to quality and risk management, laid down in this Regulation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(23)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Directive 98/79/EC of the European Parliament and of the Council <a href=\"#ntr16-L_2017117EN.01000101-E0016\" id=\"ntc16-L_2017117EN.01000101-E0016\">(<span class=\"oj-super oj-note-tag\">16</span>)</a> allows the Commission to adopt common technical specifications for specific categories of <span class=\"oj-italic\">in vitro</span> diagnostic medical devices. In areas where no harmonised standards exist or where they are insufficient, the Commission should be empowered to lay down common specifications which provide a means of complying with the general safety and performance requirements, and the requirements for clinical investigations and clinical evaluation and/or post-market clinical follow-up, laid down in this Regulation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(23)</p>,\n",
       " <p class=\"oj-normal\">Directive 98/79/EC of the European Parliament and of the Council <a href=\"#ntr16-L_2017117EN.01000101-E0016\" id=\"ntc16-L_2017117EN.01000101-E0016\">(<span class=\"oj-super oj-note-tag\">16</span>)</a> allows the Commission to adopt common technical specifications for specific categories of <span class=\"oj-italic\">in vitro</span> diagnostic medical devices. In areas where no harmonised standards exist or where they are insufficient, the Commission should be empowered to lay down common specifications which provide a means of complying with the general safety and performance requirements, and the requirements for clinical investigations and clinical evaluation and/or post-market clinical follow-up, laid down in this Regulation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(24)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Common specifications (‘CS’) should be developed after consulting the relevant stakeholders and taking account of European and international standards.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(24)</p>,\n",
       " <p class=\"oj-normal\">Common specifications (‘CS’) should be developed after consulting the relevant stakeholders and taking account of European and international standards.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(25)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The rules applicable to devices should be aligned, where appropriate, with the New Legislative Framework for the Marketing of Products, which consists of Regulation (EC) No 765/2008 of the European Parliament and of the Council <a href=\"#ntr17-L_2017117EN.01000101-E0017\" id=\"ntc17-L_2017117EN.01000101-E0017\">(<span class=\"oj-super oj-note-tag\">17</span>)</a> and Decision No 768/2008/EC of the European Parliament and of the Council <a href=\"#ntr18-L_2017117EN.01000101-E0018\" id=\"ntc18-L_2017117EN.01000101-E0018\">(<span class=\"oj-super oj-note-tag\">18</span>)</a>.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(25)</p>,\n",
       " <p class=\"oj-normal\">The rules applicable to devices should be aligned, where appropriate, with the New Legislative Framework for the Marketing of Products, which consists of Regulation (EC) No 765/2008 of the European Parliament and of the Council <a href=\"#ntr17-L_2017117EN.01000101-E0017\" id=\"ntc17-L_2017117EN.01000101-E0017\">(<span class=\"oj-super oj-note-tag\">17</span>)</a> and Decision No 768/2008/EC of the European Parliament and of the Council <a href=\"#ntr18-L_2017117EN.01000101-E0018\" id=\"ntc18-L_2017117EN.01000101-E0018\">(<span class=\"oj-super oj-note-tag\">18</span>)</a>.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(26)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The rules on Union market surveillance and control of products entering the Union market laid down in Regulation (EC) No 765/2008 apply to devices covered by this Regulation which does not prevent Member States from choosing the competent authorities to carry out those tasks.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(26)</p>,\n",
       " <p class=\"oj-normal\">The rules on Union market surveillance and control of products entering the Union market laid down in Regulation (EC) No 765/2008 apply to devices covered by this Regulation which does not prevent Member States from choosing the competent authorities to carry out those tasks.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(27)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">It is appropriate to set out clearly the general obligations of the different economic operators, including importers and distributors, building on the New Legislative Framework for the Marketing of Products, without prejudice to the specific obligations laid down in the various parts of this Regulation, to enhance understanding of the requirements laid down in this Regulation and thus to improve regulatory compliance by the relevant operators.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(27)</p>,\n",
       " <p class=\"oj-normal\">It is appropriate to set out clearly the general obligations of the different economic operators, including importers and distributors, building on the New Legislative Framework for the Marketing of Products, without prejudice to the specific obligations laid down in the various parts of this Regulation, to enhance understanding of the requirements laid down in this Regulation and thus to improve regulatory compliance by the relevant operators.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(28)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">For the purpose of this Regulation, the activities of distributors should be deemed to include acquisition, holding and supplying of devices.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(28)</p>,\n",
       " <p class=\"oj-normal\">For the purpose of this Regulation, the activities of distributors should be deemed to include acquisition, holding and supplying of devices.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(29)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Several of the obligations on manufacturers, such as clinical evaluation or vigilance reporting, that were set out only in the Annexes to Directives 90/385/EEC and 93/42/EEC, should be incorporated into the enacting provisions of this Regulation to facilitate its application.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(29)</p>,\n",
       " <p class=\"oj-normal\">Several of the obligations on manufacturers, such as clinical evaluation or vigilance reporting, that were set out only in the Annexes to Directives 90/385/EEC and 93/42/EEC, should be incorporated into the enacting provisions of this Regulation to facilitate its application.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(30)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Health institutions should have the possibility of manufacturing, modifying and using devices in-house and thereby address, on a non-industrial scale, the specific needs of target patient groups which cannot be met at the appropriate level of performance by an equivalent device available on the market. In that context, it is appropriate to provide that certain rules of this Regulation, as regards medical devices manufactured and used only within health institutions, including hospitals as well as institutions, such as laboratories and public health institutes that support the healthcare system and/or address patient needs, but which do not treat or care for patients directly, should not apply, since the aims of this Regulation would still be met in a proportionate manner. It should be noted that the concept of ‘health institution’ does not cover establishments primarily claiming to pursue health interests or healthy lifestyles, such as gyms, spas, wellness and fitness centres. As a result, the exemption applicable to health institutions does not apply to such establishments.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(30)</p>,\n",
       " <p class=\"oj-normal\">Health institutions should have the possibility of manufacturing, modifying and using devices in-house and thereby address, on a non-industrial scale, the specific needs of target patient groups which cannot be met at the appropriate level of performance by an equivalent device available on the market. In that context, it is appropriate to provide that certain rules of this Regulation, as regards medical devices manufactured and used only within health institutions, including hospitals as well as institutions, such as laboratories and public health institutes that support the healthcare system and/or address patient needs, but which do not treat or care for patients directly, should not apply, since the aims of this Regulation would still be met in a proportionate manner. It should be noted that the concept of ‘health institution’ does not cover establishments primarily claiming to pursue health interests or healthy lifestyles, such as gyms, spas, wellness and fitness centres. As a result, the exemption applicable to health institutions does not apply to such establishments.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(31)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In view of the fact that natural or legal persons can claim compensation for damage caused by a defective device in accordance with applicable Union and national law, it is appropriate to require manufacturers to have measures in place to provide sufficient financial coverage in respect of their potential liability under Council Directive 85/374/EEC <a href=\"#ntr19-L_2017117EN.01000101-E0019\" id=\"ntc19-L_2017117EN.01000101-E0019\">(<span class=\"oj-super oj-note-tag\">19</span>)</a>. Such measures should be proportionate to the risk class, type of device and the size of the enterprise. In this context, it is also appropriate to lay down rules concerning the facilitation, by a competent authority, of the provision of information to persons who may have been injured by a defective device.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(31)</p>,\n",
       " <p class=\"oj-normal\">In view of the fact that natural or legal persons can claim compensation for damage caused by a defective device in accordance with applicable Union and national law, it is appropriate to require manufacturers to have measures in place to provide sufficient financial coverage in respect of their potential liability under Council Directive 85/374/EEC <a href=\"#ntr19-L_2017117EN.01000101-E0019\" id=\"ntc19-L_2017117EN.01000101-E0019\">(<span class=\"oj-super oj-note-tag\">19</span>)</a>. Such measures should be proportionate to the risk class, type of device and the size of the enterprise. In this context, it is also appropriate to lay down rules concerning the facilitation, by a competent authority, of the provision of information to persons who may have been injured by a defective device.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(32)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">To ensure that devices manufactured in series production continue to be in conformity with the requirements of this Regulation and that experience from the use of the devices they manufacture is taken into account for the production process, all manufacturers should have a quality management system and a post-market surveillance system in place which should be proportionate to the risk class and the type of the device in question. In addition, in order to minimize risks or prevent incidents related to devices, manufacturers should establish a system for risk management and a system for reporting of incidents and field safety corrective actions.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(32)</p>,\n",
       " <p class=\"oj-normal\">To ensure that devices manufactured in series production continue to be in conformity with the requirements of this Regulation and that experience from the use of the devices they manufacture is taken into account for the production process, all manufacturers should have a quality management system and a post-market surveillance system in place which should be proportionate to the risk class and the type of the device in question. In addition, in order to minimize risks or prevent incidents related to devices, manufacturers should establish a system for risk management and a system for reporting of incidents and field safety corrective actions.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(33)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The risk management system should be carefully aligned with and reflected in the clinical evaluation for the device, including the clinical risks to be addressed as part of clinical investigations, clinical evaluation and post-market clinical follow up. The risk management and clinical evaluation processes should be inter-dependent and should be regularly updated.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(33)</p>,\n",
       " <p class=\"oj-normal\">The risk management system should be carefully aligned with and reflected in the clinical evaluation for the device, including the clinical risks to be addressed as part of clinical investigations, clinical evaluation and post-market clinical follow up. The risk management and clinical evaluation processes should be inter-dependent and should be regularly updated.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(34)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">It should be ensured that supervision and control of the manufacture of devices, and the post-market surveillance and vigilance activities concerning them, are carried out within the manufacturer's organisation by a person responsible for regulatory compliance who fulfils minimum conditions of qualification.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(34)</p>,\n",
       " <p class=\"oj-normal\">It should be ensured that supervision and control of the manufacture of devices, and the post-market surveillance and vigilance activities concerning them, are carried out within the manufacturer's organisation by a person responsible for regulatory compliance who fulfils minimum conditions of qualification.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(35)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">For manufacturers who are not established in the Union, the authorised representative plays a pivotal role in ensuring the compliance of the devices produced by those manufacturers and in serving as their contact person established in the Union. Given that pivotal role, for the purposes of enforcement it is appropriate to make the authorised representative legally liable for defective devices in the event that a manufacturer established outside the Union has not complied with its general obligations. The liability of the authorised representative provided for in this Regulation is without prejudice to the provisions of Directive 85/374/EEC, and accordingly the authorised representative should be jointly and severally liable with the importer and the manufacturer. The tasks of an authorised representative should be defined in a written mandate. Considering the role of authorised representatives, the minimum requirements they should meet should be clearly defined, including the requirement of having available a person who fulfils minimum conditions of qualification which should be similar to those for a manufacturer's person responsible for regulatory compliance.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(35)</p>,\n",
       " <p class=\"oj-normal\">For manufacturers who are not established in the Union, the authorised representative plays a pivotal role in ensuring the compliance of the devices produced by those manufacturers and in serving as their contact person established in the Union. Given that pivotal role, for the purposes of enforcement it is appropriate to make the authorised representative legally liable for defective devices in the event that a manufacturer established outside the Union has not complied with its general obligations. The liability of the authorised representative provided for in this Regulation is without prejudice to the provisions of Directive 85/374/EEC, and accordingly the authorised representative should be jointly and severally liable with the importer and the manufacturer. The tasks of an authorised representative should be defined in a written mandate. Considering the role of authorised representatives, the minimum requirements they should meet should be clearly defined, including the requirement of having available a person who fulfils minimum conditions of qualification which should be similar to those for a manufacturer's person responsible for regulatory compliance.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(36)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">To ensure legal certainty in respect of the obligations incumbent on economic operators, it is necessary to clarify when a distributor, importer or other person is to be considered the manufacturer of a device.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(36)</p>,\n",
       " <p class=\"oj-normal\">To ensure legal certainty in respect of the obligations incumbent on economic operators, it is necessary to clarify when a distributor, importer or other person is to be considered the manufacturer of a device.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(37)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Parallel trade in products already placed on the market is a lawful form of trade within the internal market on the basis of Article 34 TFEU subject to the limitations arising from the need for protection of health and safety and from the need for protection of intellectual property rights provided for under Article 36 TFEU. Application of the principle of parallel trade is, however, subject to different interpretations in the Member States. The conditions, in particular the requirements for relabelling and repackaging, should therefore be specified in this Regulation, taking into account the case-law of the Court of Justice <a href=\"#ntr20-L_2017117EN.01000101-E0020\" id=\"ntc20-L_2017117EN.01000101-E0020\">(<span class=\"oj-super oj-note-tag\">20</span>)</a> in other relevant sectors and existing good practice in the field of medical devices.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(37)</p>,\n",
       " <p class=\"oj-normal\">Parallel trade in products already placed on the market is a lawful form of trade within the internal market on the basis of Article 34 TFEU subject to the limitations arising from the need for protection of health and safety and from the need for protection of intellectual property rights provided for under Article 36 TFEU. Application of the principle of parallel trade is, however, subject to different interpretations in the Member States. The conditions, in particular the requirements for relabelling and repackaging, should therefore be specified in this Regulation, taking into account the case-law of the Court of Justice <a href=\"#ntr20-L_2017117EN.01000101-E0020\" id=\"ntc20-L_2017117EN.01000101-E0020\">(<span class=\"oj-super oj-note-tag\">20</span>)</a> in other relevant sectors and existing good practice in the field of medical devices.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(38)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The reprocessing and further use of single-use devices should only take place where permitted by national law and while complying with the requirements laid down in this Regulation. The reprocessor of a single-use device should be considered to be the manufacturer of the reprocessed device and should assume the obligations incumbent on manufacturers under this Regulation. Nevertheless, Member States should have the possibility of deciding that the obligations relating to reprocessing and re-use of single-use devices within a health institution or by an external reprocessor acting on its behalf may differ from the obligations on a manufacturer described in this Regulation. In principle, such divergence should only be permitted where reprocessing and reuse of single-use devices within a health institution or by an external reprocessor are compliant with CS that have been adopted, or, in the absence of such CS, with relevant harmonised standards and national provisions. The reprocessing of such devices should ensure an equivalent level of safety and performance to that of the corresponding initial single-use device.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(38)</p>,\n",
       " <p class=\"oj-normal\">The reprocessing and further use of single-use devices should only take place where permitted by national law and while complying with the requirements laid down in this Regulation. The reprocessor of a single-use device should be considered to be the manufacturer of the reprocessed device and should assume the obligations incumbent on manufacturers under this Regulation. Nevertheless, Member States should have the possibility of deciding that the obligations relating to reprocessing and re-use of single-use devices within a health institution or by an external reprocessor acting on its behalf may differ from the obligations on a manufacturer described in this Regulation. In principle, such divergence should only be permitted where reprocessing and reuse of single-use devices within a health institution or by an external reprocessor are compliant with CS that have been adopted, or, in the absence of such CS, with relevant harmonised standards and national provisions. The reprocessing of such devices should ensure an equivalent level of safety and performance to that of the corresponding initial single-use device.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(39)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Patients who are implanted with a device should be given clear and easily accessible essential information allowing the implanted device to be identified and other relevant information about the device, including any necessary health risk warnings or precautions to be taken, for example indications as to whether or not it is compatible with certain diagnostic devices or with scanners used for security controls.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(39)</p>,\n",
       " <p class=\"oj-normal\">Patients who are implanted with a device should be given clear and easily accessible essential information allowing the implanted device to be identified and other relevant information about the device, including any necessary health risk warnings or precautions to be taken, for example indications as to whether or not it is compatible with certain diagnostic devices or with scanners used for security controls.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(40)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Devices should, as a general rule, bear the CE marking to indicate their conformity with this Regulation so that they can move freely within the Union and be put into service in accordance with their intended purpose. Member States should not create obstacles to the placing on the market or putting into service of devices that comply with the requirements laid down in this Regulation. However, Member States should be allowed to decide whether to restrict the use of any specific type of device in relation to aspects that are not covered by this Regulation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(40)</p>,\n",
       " <p class=\"oj-normal\">Devices should, as a general rule, bear the CE marking to indicate their conformity with this Regulation so that they can move freely within the Union and be put into service in accordance with their intended purpose. Member States should not create obstacles to the placing on the market or putting into service of devices that comply with the requirements laid down in this Regulation. However, Member States should be allowed to decide whether to restrict the use of any specific type of device in relation to aspects that are not covered by this Regulation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(41)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The traceability of devices by means of a Unique Device Identification system (UDI system) based on international guidance should significantly enhance the effectiveness of the post-market safety-related activities for devices, which is owing to improved incident reporting, targeted field safety corrective actions and better monitoring by competent authorities. It should also help to reduce medical errors and to fight against falsified devices. Use of the UDI system should also improve purchasing and waste disposal policies and stock-management by health institutions and other economic operators and, where possible, be compatible with other authentication systems already in place in those settings.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(41)</p>,\n",
       " <p class=\"oj-normal\">The traceability of devices by means of a Unique Device Identification system (UDI system) based on international guidance should significantly enhance the effectiveness of the post-market safety-related activities for devices, which is owing to improved incident reporting, targeted field safety corrective actions and better monitoring by competent authorities. It should also help to reduce medical errors and to fight against falsified devices. Use of the UDI system should also improve purchasing and waste disposal policies and stock-management by health institutions and other economic operators and, where possible, be compatible with other authentication systems already in place in those settings.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(42)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The UDI system should apply to all devices placed on the market except custom-made devices, and be based on internationally recognised principles including definitions that are compatible with those used by major trade partners. In order for the UDI system to become functional in time for the application of this Regulation, detailed rules should be laid down in this Regulation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(42)</p>,\n",
       " <p class=\"oj-normal\">The UDI system should apply to all devices placed on the market except custom-made devices, and be based on internationally recognised principles including definitions that are compatible with those used by major trade partners. In order for the UDI system to become functional in time for the application of this Regulation, detailed rules should be laid down in this Regulation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(43)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Transparency and adequate access to information, appropriately presented for the intended user, are essential in the public interest, to protect public health, to empower patients and healthcare professionals and to enable them to make informed decisions, to provide a sound basis for regulatory decision-making and to build confidence in the regulatory system.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(43)</p>,\n",
       " <p class=\"oj-normal\">Transparency and adequate access to information, appropriately presented for the intended user, are essential in the public interest, to protect public health, to empower patients and healthcare professionals and to enable them to make informed decisions, to provide a sound basis for regulatory decision-making and to build confidence in the regulatory system.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(44)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">One key aspect in fulfilling the objectives of this Regulation is the creation of a European database on medical devices (Eudamed) that should integrate different electronic systems to collate and process information regarding devices on the market and the relevant economic operators, certain aspects of conformity assessment, notified bodies, certificates, clinical investigations, vigilance and market surveillance. The objectives of the database are to enhance overall transparency, including through better access to information for the public and healthcare professionals, to avoid multiple reporting requirements, to enhance coordination between Member States and to streamline and facilitate the flow of information between economic operators, notified bodies or sponsors and Member States as well as between Member States among themselves and with the Commission. Within the internal market, this can be ensured effectively only at Union level and the Commission should therefore further develop and manage the European databank on medical devices set up by Commission Decision 2010/227/EU <a href=\"#ntr21-L_2017117EN.01000101-E0021\" id=\"ntc21-L_2017117EN.01000101-E0021\">(<span class=\"oj-super oj-note-tag\">21</span>)</a>.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(44)</p>,\n",
       " <p class=\"oj-normal\">One key aspect in fulfilling the objectives of this Regulation is the creation of a European database on medical devices (Eudamed) that should integrate different electronic systems to collate and process information regarding devices on the market and the relevant economic operators, certain aspects of conformity assessment, notified bodies, certificates, clinical investigations, vigilance and market surveillance. The objectives of the database are to enhance overall transparency, including through better access to information for the public and healthcare professionals, to avoid multiple reporting requirements, to enhance coordination between Member States and to streamline and facilitate the flow of information between economic operators, notified bodies or sponsors and Member States as well as between Member States among themselves and with the Commission. Within the internal market, this can be ensured effectively only at Union level and the Commission should therefore further develop and manage the European databank on medical devices set up by Commission Decision 2010/227/EU <a href=\"#ntr21-L_2017117EN.01000101-E0021\" id=\"ntc21-L_2017117EN.01000101-E0021\">(<span class=\"oj-super oj-note-tag\">21</span>)</a>.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(45)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">To facilitate the functioning of Eudamed, an internationally recognised medical device nomenclature should be available free of charge to manufacturers and other natural or legal persons required by this Regulation to use that nomenclature. Furthermore, that nomenclature should be available, where reasonably practicable, free of charge also to other stakeholders.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(45)</p>,\n",
       " <p class=\"oj-normal\">To facilitate the functioning of Eudamed, an internationally recognised medical device nomenclature should be available free of charge to manufacturers and other natural or legal persons required by this Regulation to use that nomenclature. Furthermore, that nomenclature should be available, where reasonably practicable, free of charge also to other stakeholders.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(46)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Eudamed's electronic systems regarding devices on the market, the relevant economic operators and certificates should enable the public to be adequately informed about devices on the Union market. The electronic system on clinical investigations should serve as a tool for the cooperation between Member States and for enabling sponsors to submit, on a voluntary basis, a single application for several Member States and to report serious adverse events, device deficiencies and related updates. The electronic system on vigilance should enable manufacturers to report serious incidents and other reportable events and to support the coordination of the evaluation of such incidents and events by competent authorities. The electronic system regarding market surveillance should be a tool for the exchange of information between competent authorities.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(46)</p>,\n",
       " <p class=\"oj-normal\">Eudamed's electronic systems regarding devices on the market, the relevant economic operators and certificates should enable the public to be adequately informed about devices on the Union market. The electronic system on clinical investigations should serve as a tool for the cooperation between Member States and for enabling sponsors to submit, on a voluntary basis, a single application for several Member States and to report serious adverse events, device deficiencies and related updates. The electronic system on vigilance should enable manufacturers to report serious incidents and other reportable events and to support the coordination of the evaluation of such incidents and events by competent authorities. The electronic system regarding market surveillance should be a tool for the exchange of information between competent authorities.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(47)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In respect of data collated and processed through the electronic systems of Eudamed, Directive 95/46/EC of the European Parliament and of the Council <a href=\"#ntr22-L_2017117EN.01000101-E0022\" id=\"ntc22-L_2017117EN.01000101-E0022\">(<span class=\"oj-super oj-note-tag\">22</span>)</a> applies to the processing of personal data carried out in the Member States, under the supervision of the Member States' competent authorities, in particular the public independent authorities designated by the Member States. Regulation (EC) No 45/2001 of the European Parliament and of the Council <a href=\"#ntr23-L_2017117EN.01000101-E0023\" id=\"ntc23-L_2017117EN.01000101-E0023\">(<span class=\"oj-super oj-note-tag\">23</span>)</a> applies to the processing of personal data carried out by the Commission within the framework of this Regulation, under the supervision of the European Data Protection Supervisor. In accordance with Regulation (EC) No 45/2001, the Commission should be designated as the controller of Eudamed and its electronic systems.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(47)</p>,\n",
       " <p class=\"oj-normal\">In respect of data collated and processed through the electronic systems of Eudamed, Directive 95/46/EC of the European Parliament and of the Council <a href=\"#ntr22-L_2017117EN.01000101-E0022\" id=\"ntc22-L_2017117EN.01000101-E0022\">(<span class=\"oj-super oj-note-tag\">22</span>)</a> applies to the processing of personal data carried out in the Member States, under the supervision of the Member States' competent authorities, in particular the public independent authorities designated by the Member States. Regulation (EC) No 45/2001 of the European Parliament and of the Council <a href=\"#ntr23-L_2017117EN.01000101-E0023\" id=\"ntc23-L_2017117EN.01000101-E0023\">(<span class=\"oj-super oj-note-tag\">23</span>)</a> applies to the processing of personal data carried out by the Commission within the framework of this Regulation, under the supervision of the European Data Protection Supervisor. In accordance with Regulation (EC) No 45/2001, the Commission should be designated as the controller of Eudamed and its electronic systems.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(48)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">For implantable devices and for class III devices, manufacturers should summarise the main safety and performance aspects of the device and the outcome of the clinical evaluation in a document that should be publicly available.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(48)</p>,\n",
       " <p class=\"oj-normal\">For implantable devices and for class III devices, manufacturers should summarise the main safety and performance aspects of the device and the outcome of the clinical evaluation in a document that should be publicly available.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(49)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The summary of safety and clinical performance for a device should include in particular the place of the device in the context of diagnostic or therapeutic options taking into account the clinical evaluation of that device when compared to the diagnostic or therapeutic alternatives and the specific conditions under which that device and its alternatives can be considered.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(49)</p>,\n",
       " <p class=\"oj-normal\">The summary of safety and clinical performance for a device should include in particular the place of the device in the context of diagnostic or therapeutic options taking into account the clinical evaluation of that device when compared to the diagnostic or therapeutic alternatives and the specific conditions under which that device and its alternatives can be considered.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(50)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The proper functioning of notified bodies is crucial for ensuring a high level of health and safety protection and citizens' confidence in the system. Designation and monitoring of notified bodies by the Member States, in accordance with detailed and strict criteria, should therefore be subject to controls at Union level.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(50)</p>,\n",
       " <p class=\"oj-normal\">The proper functioning of notified bodies is crucial for ensuring a high level of health and safety protection and citizens' confidence in the system. Designation and monitoring of notified bodies by the Member States, in accordance with detailed and strict criteria, should therefore be subject to controls at Union level.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(51)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Notified bodies' assessments of manufacturers' technical documentation, in particular documentation on clinical evaluation, should be critically evaluated by the authority responsible for notified bodies. That evaluation should be part of the risk-based approach to the oversight and monitoring activities of notified bodies and should be based on sampling of the relevant documentation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(51)</p>,\n",
       " <p class=\"oj-normal\">Notified bodies' assessments of manufacturers' technical documentation, in particular documentation on clinical evaluation, should be critically evaluated by the authority responsible for notified bodies. That evaluation should be part of the risk-based approach to the oversight and monitoring activities of notified bodies and should be based on sampling of the relevant documentation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(52)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The position of notified bodies vis-à-vis manufacturers should be strengthened, including with regard to their right and duty to carry out unannounced on-site audits and to conduct physical or laboratory tests on devices to ensure continuous compliance by manufacturers after receipt of the original certification.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(52)</p>,\n",
       " <p class=\"oj-normal\">The position of notified bodies vis-à-vis manufacturers should be strengthened, including with regard to their right and duty to carry out unannounced on-site audits and to conduct physical or laboratory tests on devices to ensure continuous compliance by manufacturers after receipt of the original certification.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(53)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">To increase transparency with regard to the oversight of notified bodies by national authorities, the authorities responsible for notified bodies should publish information on the national measures governing the assessment, designation and monitoring of notified bodies. In accordance with good administrative practice, this information should be kept up to date by those authorities in particular to reflect relevant, significant or substantive changes to the procedures in question.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(53)</p>,\n",
       " <p class=\"oj-normal\">To increase transparency with regard to the oversight of notified bodies by national authorities, the authorities responsible for notified bodies should publish information on the national measures governing the assessment, designation and monitoring of notified bodies. In accordance with good administrative practice, this information should be kept up to date by those authorities in particular to reflect relevant, significant or substantive changes to the procedures in question.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(54)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The Member State in which a notified body is established should be responsible for enforcing the requirements of this Regulation with regard to that notified body.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(54)</p>,\n",
       " <p class=\"oj-normal\">The Member State in which a notified body is established should be responsible for enforcing the requirements of this Regulation with regard to that notified body.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(55)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In view, in particular, of the responsibility of Member States for the organisation and delivery of health services and medical care, they should be allowed to lay down additional requirements on notified bodies designated for the conformity assessment of devices and established on their territory as far as issues that are not regulated in this Regulation are concerned. Any such additional requirements laid down should not affect more specific horizontal Union legislation on notified bodies and equal treatment of notified bodies.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(55)</p>,\n",
       " <p class=\"oj-normal\">In view, in particular, of the responsibility of Member States for the organisation and delivery of health services and medical care, they should be allowed to lay down additional requirements on notified bodies designated for the conformity assessment of devices and established on their territory as far as issues that are not regulated in this Regulation are concerned. Any such additional requirements laid down should not affect more specific horizontal Union legislation on notified bodies and equal treatment of notified bodies.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(56)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">For class III implantable devices and class IIb active devices intended to administer and/or remove a medicinal product, notified bodies should, except in certain cases, be obliged to request expert panels to scrutinise their clinical evaluation assessment report. Competent authorities should be informed about devices that have been granted a certificate following a conformity assessment procedure involving an expert panel. The consultation of expert panels in relation to the clinical evaluation should lead to a harmonised evaluation of high-risk medical devices by sharing expertise on clinical aspects and developing CS on categories of devices that have undergone that consultation process.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(56)</p>,\n",
       " <p class=\"oj-normal\">For class III implantable devices and class IIb active devices intended to administer and/or remove a medicinal product, notified bodies should, except in certain cases, be obliged to request expert panels to scrutinise their clinical evaluation assessment report. Competent authorities should be informed about devices that have been granted a certificate following a conformity assessment procedure involving an expert panel. The consultation of expert panels in relation to the clinical evaluation should lead to a harmonised evaluation of high-risk medical devices by sharing expertise on clinical aspects and developing CS on categories of devices that have undergone that consultation process.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(57)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">For class III devices and for certain class IIb devices, a manufacturer should be able to consult voluntarily an expert panel, prior to that manufacturer's clinical evaluation and/or investigation, on its clinical development strategy and on proposals for clinical investigations.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(57)</p>,\n",
       " <p class=\"oj-normal\">For class III devices and for certain class IIb devices, a manufacturer should be able to consult voluntarily an expert panel, prior to that manufacturer's clinical evaluation and/or investigation, on its clinical development strategy and on proposals for clinical investigations.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(58)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">It is necessary, in particular for the purpose of the conformity assessment procedures, to maintain the division of devices into four product classes in line with international practice. The classification rules, which are based on the vulnerability of the human body, should take into account the potential risks associated with the technical design and manufacture of the devices. To maintain the same level of safety as provided by Directive 90/385/EEC, active implantable devices should be in the highest risk class.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(58)</p>,\n",
       " <p class=\"oj-normal\">It is necessary, in particular for the purpose of the conformity assessment procedures, to maintain the division of devices into four product classes in line with international practice. The classification rules, which are based on the vulnerability of the human body, should take into account the potential risks associated with the technical design and manufacture of the devices. To maintain the same level of safety as provided by Directive 90/385/EEC, active implantable devices should be in the highest risk class.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(59)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Rules under the old regime applied to invasive devices do not sufficiently take account of the level of invasiveness and potential toxicity of certain devices which are introduced into the human body. In order to obtain a suitable risk-based classification of devices that are composed of substances or of combinations of substances that are absorbed by or locally dispersed in the human body, it is necessary to introduce specific classification rules for such devices. The classification rules should take into account the place where the device performs its action in or on the human body, where it is introduced or applied, and whether a systemic absorption of the substances of which the device is composed, or of the products of metabolism in the human body of those substances occurs.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(59)</p>,\n",
       " <p class=\"oj-normal\">Rules under the old regime applied to invasive devices do not sufficiently take account of the level of invasiveness and potential toxicity of certain devices which are introduced into the human body. In order to obtain a suitable risk-based classification of devices that are composed of substances or of combinations of substances that are absorbed by or locally dispersed in the human body, it is necessary to introduce specific classification rules for such devices. The classification rules should take into account the place where the device performs its action in or on the human body, where it is introduced or applied, and whether a systemic absorption of the substances of which the device is composed, or of the products of metabolism in the human body of those substances occurs.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(60)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The conformity assessment procedure for class I devices should be carried out, as a general rule, under the sole responsibility of manufacturers in view of the low level of vulnerability associated with such devices. For class IIa, class IIb and class III devices, an appropriate level of involvement of a notified body should be compulsory.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(60)</p>,\n",
       " <p class=\"oj-normal\">The conformity assessment procedure for class I devices should be carried out, as a general rule, under the sole responsibility of manufacturers in view of the low level of vulnerability associated with such devices. For class IIa, class IIb and class III devices, an appropriate level of involvement of a notified body should be compulsory.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(61)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The conformity assessment procedures for devices should be further strengthened and streamlined whilst the requirements for notified bodies as regards the performance of their assessments should be clearly specified to ensure a level playing field.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(61)</p>,\n",
       " <p class=\"oj-normal\">The conformity assessment procedures for devices should be further strengthened and streamlined whilst the requirements for notified bodies as regards the performance of their assessments should be clearly specified to ensure a level playing field.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(62)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">It is appropriate that certificates of free sale contain information that makes it possible to use Eudamed in order to obtain information on the device, in particular with regard to whether it is on the market, withdrawn from the market or recalled, and on any certificate on its conformity.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(62)</p>,\n",
       " <p class=\"oj-normal\">It is appropriate that certificates of free sale contain information that makes it possible to use Eudamed in order to obtain information on the device, in particular with regard to whether it is on the market, withdrawn from the market or recalled, and on any certificate on its conformity.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(63)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">To ensure a high level of safety and performance, demonstration of compliance with the general safety and performance requirements laid down in this Regulation should be based on clinical data that, for class III devices and implantable devices should, as a general rule, be sourced from clinical investigations that have been carried out under the responsibility of a sponsor. It should be possible both for the manufacturer and for another natural or legal person to be the sponsor taking responsibility for the clinical investigation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(63)</p>,\n",
       " <p class=\"oj-normal\">To ensure a high level of safety and performance, demonstration of compliance with the general safety and performance requirements laid down in this Regulation should be based on clinical data that, for class III devices and implantable devices should, as a general rule, be sourced from clinical investigations that have been carried out under the responsibility of a sponsor. It should be possible both for the manufacturer and for another natural or legal person to be the sponsor taking responsibility for the clinical investigation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(64)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The rules on clinical investigations should be in line with well-established international guidance in this field, such as the international standard ISO 14155:2011 on good clinical practice for clinical investigations of medical devices for human subjects, so as to make it easier for the results of clinical investigations conducted in the Union to be accepted as documentation outside the Union and to make it easier for the results of clinical investigations conducted outside the Union in accordance with international guidelines to be accepted within the Union. In addition, the rules should be in line with the most recent version of the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(64)</p>,\n",
       " <p class=\"oj-normal\">The rules on clinical investigations should be in line with well-established international guidance in this field, such as the international standard ISO 14155:2011 on good clinical practice for clinical investigations of medical devices for human subjects, so as to make it easier for the results of clinical investigations conducted in the Union to be accepted as documentation outside the Union and to make it easier for the results of clinical investigations conducted outside the Union in accordance with international guidelines to be accepted within the Union. In addition, the rules should be in line with the most recent version of the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(65)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">It should be left to the Member State where a clinical investigation is to be conducted to determine the appropriate authority to be involved in the assessment of the application to conduct a clinical investigation and to organise the involvement of ethics committees within the timelines for the authorisation of that clinical investigation as set out in this Regulation. Such decisions are a matter of internal organisation for each Member State. In that context, Member States should ensure the involvement of laypersons, in particular patients or patients' organisations. They should also ensure that the necessary expertise is available.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(65)</p>,\n",
       " <p class=\"oj-normal\">It should be left to the Member State where a clinical investigation is to be conducted to determine the appropriate authority to be involved in the assessment of the application to conduct a clinical investigation and to organise the involvement of ethics committees within the timelines for the authorisation of that clinical investigation as set out in this Regulation. Such decisions are a matter of internal organisation for each Member State. In that context, Member States should ensure the involvement of laypersons, in particular patients or patients' organisations. They should also ensure that the necessary expertise is available.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(66)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Where, in the course of a clinical investigation, harm caused to a subject leads to the civil or criminal liability of the investigator or the sponsor being invoked, the conditions for liability in such cases, including issues of causality and the level of damages and sanctions, should remain governed by national law.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(66)</p>,\n",
       " <p class=\"oj-normal\">Where, in the course of a clinical investigation, harm caused to a subject leads to the civil or criminal liability of the investigator or the sponsor being invoked, the conditions for liability in such cases, including issues of causality and the level of damages and sanctions, should remain governed by national law.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(67)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">An electronic system should be set up at Union level to ensure that every clinical investigation is recorded and reported in a publicly accessible database. To protect the right to the protection of personal data, recognised by Article 8 of the Charter of Fundamental Rights of the European Union (‘the Charter’), no personal data of subjects participating in a clinical investigation should be recorded in the electronic system. To ensure synergies with the area of clinical trials on medicinal products, the electronic system on clinical investigations should be interoperable with the EU database to be set up for clinical trials on medicinal products for human use.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(67)</p>,\n",
       " <p class=\"oj-normal\">An electronic system should be set up at Union level to ensure that every clinical investigation is recorded and reported in a publicly accessible database. To protect the right to the protection of personal data, recognised by Article 8 of the Charter of Fundamental Rights of the European Union (‘the Charter’), no personal data of subjects participating in a clinical investigation should be recorded in the electronic system. To ensure synergies with the area of clinical trials on medicinal products, the electronic system on clinical investigations should be interoperable with the EU database to be set up for clinical trials on medicinal products for human use.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(68)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Where a clinical investigation is to be conducted in more than one Member State, the sponsor should have the possibility of submitting a single application in order to reduce administrative burden. In order to allow for resource-sharing and to ensure consistency regarding the assessment of the health and safety-related aspects of the investigational device and of the scientific design of that clinical investigation, the procedure for the assessment of such single application should be coordinated between the Member States under the direction of a coordinating Member State. Such coordinated assessment should not include the assessment of intrinsically national, local and ethical aspects of a clinical investigation, including informed consent. For an initial period of seven years from the date of application of this Regulation, Member States should be able to participate on a voluntary basis in the coordinated assessment. After that period, all Member States should be obliged to participate in the coordinated assessment. The Commission, based on the experience gained from the voluntary coordination between Member States, should draw up a report on the application of the relevant provisions regarding the coordinated assessment procedure. In the event that the findings of the report are negative, the Commission should submit a proposal to extend the period of participation on a voluntary basis in the coordinated assessment procedure.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(68)</p>,\n",
       " <p class=\"oj-normal\">Where a clinical investigation is to be conducted in more than one Member State, the sponsor should have the possibility of submitting a single application in order to reduce administrative burden. In order to allow for resource-sharing and to ensure consistency regarding the assessment of the health and safety-related aspects of the investigational device and of the scientific design of that clinical investigation, the procedure for the assessment of such single application should be coordinated between the Member States under the direction of a coordinating Member State. Such coordinated assessment should not include the assessment of intrinsically national, local and ethical aspects of a clinical investigation, including informed consent. For an initial period of seven years from the date of application of this Regulation, Member States should be able to participate on a voluntary basis in the coordinated assessment. After that period, all Member States should be obliged to participate in the coordinated assessment. The Commission, based on the experience gained from the voluntary coordination between Member States, should draw up a report on the application of the relevant provisions regarding the coordinated assessment procedure. In the event that the findings of the report are negative, the Commission should submit a proposal to extend the period of participation on a voluntary basis in the coordinated assessment procedure.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(69)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Sponsors should report certain adverse events and device deficiencies that occur during clinical investigations to the Member States in which those clinical investigations are being conducted. Member States should have the possibility of terminating or suspending the investigations or revoking the authorisation for those investigations, if considered necessary to ensure a high level of protection of the subjects participating in a clinical investigation. Such information should be communicated to the other Member States.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(69)</p>,\n",
       " <p class=\"oj-normal\">Sponsors should report certain adverse events and device deficiencies that occur during clinical investigations to the Member States in which those clinical investigations are being conducted. Member States should have the possibility of terminating or suspending the investigations or revoking the authorisation for those investigations, if considered necessary to ensure a high level of protection of the subjects participating in a clinical investigation. Such information should be communicated to the other Member States.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(70)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The sponsor of a clinical investigation should submit a summary of results of the clinical investigation that is easily understandable for the intended user together with the clinical investigation report, where applicable, within the timelines laid down in this Regulation. Where it is not possible to submit the summary of the results within the defined timelines for scientific reasons, the sponsor should justify this and specify when the results will be submitted.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(70)</p>,\n",
       " <p class=\"oj-normal\">The sponsor of a clinical investigation should submit a summary of results of the clinical investigation that is easily understandable for the intended user together with the clinical investigation report, where applicable, within the timelines laid down in this Regulation. Where it is not possible to submit the summary of the results within the defined timelines for scientific reasons, the sponsor should justify this and specify when the results will be submitted.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(71)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">This Regulation should cover clinical investigations intended to gather clinical evidence for the purpose of demonstrating conformity of devices and should also lay down basic requirements regarding ethical and scientific assessments for other types of clinical investigations of medical devices.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(71)</p>,\n",
       " <p class=\"oj-normal\">This Regulation should cover clinical investigations intended to gather clinical evidence for the purpose of demonstrating conformity of devices and should also lay down basic requirements regarding ethical and scientific assessments for other types of clinical investigations of medical devices.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(72)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Incapacitated subjects, minors, pregnant women and breastfeeding women require specific protection measures. However, it should be left to Member States to determine the legally designated representatives of incapacitated subjects and minors.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(72)</p>,\n",
       " <p class=\"oj-normal\">Incapacitated subjects, minors, pregnant women and breastfeeding women require specific protection measures. However, it should be left to Member States to determine the legally designated representatives of incapacitated subjects and minors.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(73)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The principles of replacement, reduction and refinement in the area of animal experimentation laid down in the Directive 2010/63/EU of the European Parliament and of the Council <a href=\"#ntr24-L_2017117EN.01000101-E0024\" id=\"ntc24-L_2017117EN.01000101-E0024\">(<span class=\"oj-super oj-note-tag\">24</span>)</a> should be observed. In particular, the unnecessary duplication of tests and studies should be avoided.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(73)</p>,\n",
       " <p class=\"oj-normal\">The principles of replacement, reduction and refinement in the area of animal experimentation laid down in the Directive 2010/63/EU of the European Parliament and of the Council <a href=\"#ntr24-L_2017117EN.01000101-E0024\" id=\"ntc24-L_2017117EN.01000101-E0024\">(<span class=\"oj-super oj-note-tag\">24</span>)</a> should be observed. In particular, the unnecessary duplication of tests and studies should be avoided.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(74)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Manufacturers should play an active role during the post-market phase by systematically and actively gathering information from post-market experience with their devices in order to update their technical documentation and cooperate with the national competent authorities in charge of vigilance and market surveillance activities. To this end, manufacturers should establish a comprehensive post-market surveillance system, set up under their quality management system and based on a post-market surveillance plan. Relevant data and information gathered through post-market surveillance, as well as lessons learned from any implemented preventive and/or corrective actions, should be used to update any relevant part of technical documentation, such as those relating to risk assessment and clinical evaluation, and should also serve the purpose of transparency.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(74)</p>,\n",
       " <p class=\"oj-normal\">Manufacturers should play an active role during the post-market phase by systematically and actively gathering information from post-market experience with their devices in order to update their technical documentation and cooperate with the national competent authorities in charge of vigilance and market surveillance activities. To this end, manufacturers should establish a comprehensive post-market surveillance system, set up under their quality management system and based on a post-market surveillance plan. Relevant data and information gathered through post-market surveillance, as well as lessons learned from any implemented preventive and/or corrective actions, should be used to update any relevant part of technical documentation, such as those relating to risk assessment and clinical evaluation, and should also serve the purpose of transparency.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(75)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In order to better protect health and safety regarding devices on the market, the electronic system on vigilance for devices should be made more effective by creating a central portal at Union level for reporting serious incidents and field safety corrective actions.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(75)</p>,\n",
       " <p class=\"oj-normal\">In order to better protect health and safety regarding devices on the market, the electronic system on vigilance for devices should be made more effective by creating a central portal at Union level for reporting serious incidents and field safety corrective actions.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(76)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Member States should take appropriate measures to raise awareness among healthcare professionals, users and patients about the importance of reporting incidents. Healthcare professionals, users and patients should be encouraged and enabled to report suspected serious incidents at national level using harmonised formats. The national competent authorities should inform manufacturers of any suspected serious incidents and, where a manufacturer confirms that such an incident has occurred, the authorities concerned should ensure that appropriate follow-up action is taken in order to minimise recurrence of such incidents.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(76)</p>,\n",
       " <p class=\"oj-normal\">Member States should take appropriate measures to raise awareness among healthcare professionals, users and patients about the importance of reporting incidents. Healthcare professionals, users and patients should be encouraged and enabled to report suspected serious incidents at national level using harmonised formats. The national competent authorities should inform manufacturers of any suspected serious incidents and, where a manufacturer confirms that such an incident has occurred, the authorities concerned should ensure that appropriate follow-up action is taken in order to minimise recurrence of such incidents.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(77)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The evaluation of reported serious incidents and field safety corrective actions should be conducted at national level but coordination should be ensured where similar incidents have occurred or field safety corrective actions have to be carried out in more than one Member State, with the objective of sharing resources and ensuring consistency regarding the corrective action.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(77)</p>,\n",
       " <p class=\"oj-normal\">The evaluation of reported serious incidents and field safety corrective actions should be conducted at national level but coordination should be ensured where similar incidents have occurred or field safety corrective actions have to be carried out in more than one Member State, with the objective of sharing resources and ensuring consistency regarding the corrective action.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(78)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In the context of the investigation of incidents, the competent authorities should take into account, where appropriate, the information provided by and views of relevant stakeholders, including patient and healthcare professionals' organisations and manufacturers' associations.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(78)</p>,\n",
       " <p class=\"oj-normal\">In the context of the investigation of incidents, the competent authorities should take into account, where appropriate, the information provided by and views of relevant stakeholders, including patient and healthcare professionals' organisations and manufacturers' associations.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(79)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The reporting of serious adverse events or device deficiencies during clinical investigations and the reporting of serious incidents occurring after a device has been placed on the market should be clearly distinguished to avoid double reporting.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(79)</p>,\n",
       " <p class=\"oj-normal\">The reporting of serious adverse events or device deficiencies during clinical investigations and the reporting of serious incidents occurring after a device has been placed on the market should be clearly distinguished to avoid double reporting.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(80)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Rules on market surveillance should be included in this Regulation to reinforce the rights and obligations of the national competent authorities, to ensure effective coordination of their market surveillance activities and to clarify the applicable procedures.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(80)</p>,\n",
       " <p class=\"oj-normal\">Rules on market surveillance should be included in this Regulation to reinforce the rights and obligations of the national competent authorities, to ensure effective coordination of their market surveillance activities and to clarify the applicable procedures.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(81)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Any statistically significant increase in the number or severity of incidents that are not serious or in expected side-effects that could have a significant impact on the benefit-risk analysis and which could lead to unacceptable risks should be reported to the competent authorities in order to permit their assessment and the adoption of appropriate measures.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(81)</p>,\n",
       " <p class=\"oj-normal\">Any statistically significant increase in the number or severity of incidents that are not serious or in expected side-effects that could have a significant impact on the benefit-risk analysis and which could lead to unacceptable risks should be reported to the competent authorities in order to permit their assessment and the adoption of appropriate measures.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(82)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">An expert committee, the Medical Device Coordination Group (MDCG), composed of persons designated by the Member States based on their role and expertise in the field of medical devices including <span class=\"oj-italic\">in vitro</span> diagnostic medical devices, should be established to fulfil the tasks conferred on it by this Regulation and by Regulation (EU) 2017/746 of the European Parliament and of the Council <a href=\"#ntr25-L_2017117EN.01000101-E0025\" id=\"ntc25-L_2017117EN.01000101-E0025\">(<span class=\"oj-super oj-note-tag\">25</span>)</a>, to provide advice to the Commission and to assist the Commission and the Member States in ensuring a harmonised implementation of this Regulation. The MDCG should be able to establish subgroups in order to have access to necessary in-depth technical expertise in the field of medical devices including <span class=\"oj-italic\">in vitro</span> diagnostic medical devices. When establishing subgroups, appropriate consideration should be given to the possibility of involving existing groups at Union level in the field of medical devices.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(82)</p>,\n",
       " <p class=\"oj-normal\">An expert committee, the Medical Device Coordination Group (MDCG), composed of persons designated by the Member States based on their role and expertise in the field of medical devices including <span class=\"oj-italic\">in vitro</span> diagnostic medical devices, should be established to fulfil the tasks conferred on it by this Regulation and by Regulation (EU) 2017/746 of the European Parliament and of the Council <a href=\"#ntr25-L_2017117EN.01000101-E0025\" id=\"ntc25-L_2017117EN.01000101-E0025\">(<span class=\"oj-super oj-note-tag\">25</span>)</a>, to provide advice to the Commission and to assist the Commission and the Member States in ensuring a harmonised implementation of this Regulation. The MDCG should be able to establish subgroups in order to have access to necessary in-depth technical expertise in the field of medical devices including <span class=\"oj-italic\">in vitro</span> diagnostic medical devices. When establishing subgroups, appropriate consideration should be given to the possibility of involving existing groups at Union level in the field of medical devices.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(83)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Expert panels and expert laboratories should be designated by the Commission on the basis of their up-to-date clinical, scientific or technical expertise, with the aim of providing scientific, technical and clinical assistance to the Commission, the MDCG, manufacturers and notified bodies in relation to the implementation of this Regulation. Moreover, expert panels should fulfil the tasks of providing an opinion on clinical evaluation assessment reports of notified bodies in the case of certain high-risk devices.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(83)</p>,\n",
       " <p class=\"oj-normal\">Expert panels and expert laboratories should be designated by the Commission on the basis of their up-to-date clinical, scientific or technical expertise, with the aim of providing scientific, technical and clinical assistance to the Commission, the MDCG, manufacturers and notified bodies in relation to the implementation of this Regulation. Moreover, expert panels should fulfil the tasks of providing an opinion on clinical evaluation assessment reports of notified bodies in the case of certain high-risk devices.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(84)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Closer coordination between national competent authorities through information exchange and coordinated assessments under the direction of a coordinating authority is essential for ensuring a consistently high level of health and safety protection within the internal market, in particular in the areas of clinical investigations and vigilance. The principle of coordinated exchange and assessment should also apply across other authority activities described in this Regulation, such as the designation of notified bodies and should be encouraged in the area of market surveillance of devices. Joint working, coordination and communication of activities should also lead to more efficient use of resources and expertise at national level.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(84)</p>,\n",
       " <p class=\"oj-normal\">Closer coordination between national competent authorities through information exchange and coordinated assessments under the direction of a coordinating authority is essential for ensuring a consistently high level of health and safety protection within the internal market, in particular in the areas of clinical investigations and vigilance. The principle of coordinated exchange and assessment should also apply across other authority activities described in this Regulation, such as the designation of notified bodies and should be encouraged in the area of market surveillance of devices. Joint working, coordination and communication of activities should also lead to more efficient use of resources and expertise at national level.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(85)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The Commission should provide scientific, technical and corresponding logistical support to coordinating national authorities and ensure that the regulatory system for devices is effectively and uniformly implemented at Union level based on sound scientific evidence.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(85)</p>,\n",
       " <p class=\"oj-normal\">The Commission should provide scientific, technical and corresponding logistical support to coordinating national authorities and ensure that the regulatory system for devices is effectively and uniformly implemented at Union level based on sound scientific evidence.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(86)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The Union and, where appropriate, the Member States should actively participate in international regulatory cooperation in the field of medical devices to facilitate the exchange of safety-related information regarding medical devices and to foster the further development of international regulatory guidelines that promote the adoption in other jurisdictions of regulations that lead to a level of health and safety protection equivalent to that set by this Regulation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(86)</p>,\n",
       " <p class=\"oj-normal\">The Union and, where appropriate, the Member States should actively participate in international regulatory cooperation in the field of medical devices to facilitate the exchange of safety-related information regarding medical devices and to foster the further development of international regulatory guidelines that promote the adoption in other jurisdictions of regulations that lead to a level of health and safety protection equivalent to that set by this Regulation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(87)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Member States should take all necessary measures to ensure that the provisions of this Regulation are implemented, including by laying down effective, proportionate and dissuasive penalties for their infringement.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(87)</p>,\n",
       " <p class=\"oj-normal\">Member States should take all necessary measures to ensure that the provisions of this Regulation are implemented, including by laying down effective, proportionate and dissuasive penalties for their infringement.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(88)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Whilst this Regulation should not affect the right of Member States to levy fees for activities at national level, Member States should, in order to ensure transparency, inform the Commission and the other Member States before they decide on the level and structure of such fees. In order to further ensure transparency, the structure and level of the fees should be publicly available on request.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(88)</p>,\n",
       " <p class=\"oj-normal\">Whilst this Regulation should not affect the right of Member States to levy fees for activities at national level, Member States should, in order to ensure transparency, inform the Commission and the other Member States before they decide on the level and structure of such fees. In order to further ensure transparency, the structure and level of the fees should be publicly available on request.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(89)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter and in particular human dignity, the integrity of the person, the protection of personal data, the freedom of art and science, the freedom to conduct business and the right to property. This Regulation should be applied by the Member States in accordance with those rights and principles.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(89)</p>,\n",
       " <p class=\"oj-normal\">This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter and in particular human dignity, the integrity of the person, the protection of personal data, the freedom of art and science, the freedom to conduct business and the right to property. This Regulation should be applied by the Member States in accordance with those rights and principles.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(90)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The power to adopt delegated acts in accordance with Article 290 TFEU should be delegated to the Commission in order to amend certain non-essential provisions of this Regulation. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level, and that those consultations be conducted in accordance with the principles laid down in the Interinstitutional Agreement of 13 April 2016 on Better Law-Making <a href=\"#ntr26-L_2017117EN.01000101-E0026\" id=\"ntc26-L_2017117EN.01000101-E0026\">(<span class=\"oj-super oj-note-tag\">26</span>)</a>. In particular, to ensure equal participation in the preparation of delegated acts, the European Parliament and the Council receive all documents at the same time as Member States' experts, and their experts systematically have access to meetings of Commission expert groups dealing with preparation of delegated acts.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(90)</p>,\n",
       " <p class=\"oj-normal\">The power to adopt delegated acts in accordance with Article 290 TFEU should be delegated to the Commission in order to amend certain non-essential provisions of this Regulation. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level, and that those consultations be conducted in accordance with the principles laid down in the Interinstitutional Agreement of 13 April 2016 on Better Law-Making <a href=\"#ntr26-L_2017117EN.01000101-E0026\" id=\"ntc26-L_2017117EN.01000101-E0026\">(<span class=\"oj-super oj-note-tag\">26</span>)</a>. In particular, to ensure equal participation in the preparation of delegated acts, the European Parliament and the Council receive all documents at the same time as Member States' experts, and their experts systematically have access to meetings of Commission expert groups dealing with preparation of delegated acts.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(91)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In order to ensure uniform conditions for the implementation of this Regulation, implementing powers should be conferred on the Commission. Those powers should be exercised in accordance with Regulation (EU) No 182/2011 of the European Parliament and of the Council <a href=\"#ntr27-L_2017117EN.01000101-E0027\" id=\"ntc27-L_2017117EN.01000101-E0027\">(<span class=\"oj-super oj-note-tag\">27</span>)</a>.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(91)</p>,\n",
       " <p class=\"oj-normal\">In order to ensure uniform conditions for the implementation of this Regulation, implementing powers should be conferred on the Commission. Those powers should be exercised in accordance with Regulation (EU) No 182/2011 of the European Parliament and of the Council <a href=\"#ntr27-L_2017117EN.01000101-E0027\" id=\"ntc27-L_2017117EN.01000101-E0027\">(<span class=\"oj-super oj-note-tag\">27</span>)</a>.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(92)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The advisory procedure should be used for implementing acts that set out the form and presentation of the data elements of manufacturers' summaries of safety and clinical performance, and that establish the model for certificates of free sale, given that such implementing acts are of a procedural nature and do not directly have an impact on health and safety at Union level.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(92)</p>,\n",
       " <p class=\"oj-normal\">The advisory procedure should be used for implementing acts that set out the form and presentation of the data elements of manufacturers' summaries of safety and clinical performance, and that establish the model for certificates of free sale, given that such implementing acts are of a procedural nature and do not directly have an impact on health and safety at Union level.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(93)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The Commission should adopt immediately applicable implementing acts where, in duly justified cases relating to the extension to the territory of the Union of a national derogation from the applicable conformity assessment procedures, imperative grounds of urgency so require.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(93)</p>,\n",
       " <p class=\"oj-normal\">The Commission should adopt immediately applicable implementing acts where, in duly justified cases relating to the extension to the territory of the Union of a national derogation from the applicable conformity assessment procedures, imperative grounds of urgency so require.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(94)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In order to enable it to designate issuing entities, expert panels and expert laboratories, implementing powers should be conferred on the Commission.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(94)</p>,\n",
       " <p class=\"oj-normal\">In order to enable it to designate issuing entities, expert panels and expert laboratories, implementing powers should be conferred on the Commission.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(95)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">To allow economic operators, especially SMEs, notified bodies, Member States and the Commission to adapt to the changes introduced by this Regulation and to ensure its proper application, it is appropriate to provide for a sufficient transitional period for that adaptation and for the organisational arrangements that are to be made. However, certain parts of the Regulation that directly affect Member States and the Commission should be implemented as soon as possible. It is also particularly important that, by the date of application of this Regulation, a sufficient number of notified bodies be designated in accordance with the new requirements so as to avoid any shortage of medical devices on the market. Nonetheless, it is necessary that any designation of a notified body in accordance with the requirements of this Regulation prior to the date of its application be without prejudice to the validity of the designation of those notified bodies under Directives 90/385/EEC and 93/42/EEC and to their capacity to continue issuing valid certificates under those two Directives until the date of application of this Regulation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(95)</p>,\n",
       " <p class=\"oj-normal\">To allow economic operators, especially SMEs, notified bodies, Member States and the Commission to adapt to the changes introduced by this Regulation and to ensure its proper application, it is appropriate to provide for a sufficient transitional period for that adaptation and for the organisational arrangements that are to be made. However, certain parts of the Regulation that directly affect Member States and the Commission should be implemented as soon as possible. It is also particularly important that, by the date of application of this Regulation, a sufficient number of notified bodies be designated in accordance with the new requirements so as to avoid any shortage of medical devices on the market. Nonetheless, it is necessary that any designation of a notified body in accordance with the requirements of this Regulation prior to the date of its application be without prejudice to the validity of the designation of those notified bodies under Directives 90/385/EEC and 93/42/EEC and to their capacity to continue issuing valid certificates under those two Directives until the date of application of this Regulation.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(96)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In order to ensure a smooth transition to the new rules for registration of devices and of certificates, the obligation to submit the relevant information to the electronic systems set up at Union level pursuant to this Regulation should, in the event that the corresponding IT systems are developed according to plan, only become fully effective from 18 months after the date of application of this Regulation. During this transitional period, certain provisions of Directives 90/385/EEC and 93/42/EEC should remain in force. However, in order to avoid multiple registrations, economic operators and notified bodies who register in the relevant electronic systems set up at Union level pursuant to this Regulation should be considered to be in compliance with the registration requirements adopted by the Member States pursuant to those provisions.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(96)</p>,\n",
       " <p class=\"oj-normal\">In order to ensure a smooth transition to the new rules for registration of devices and of certificates, the obligation to submit the relevant information to the electronic systems set up at Union level pursuant to this Regulation should, in the event that the corresponding IT systems are developed according to plan, only become fully effective from 18 months after the date of application of this Regulation. During this transitional period, certain provisions of Directives 90/385/EEC and 93/42/EEC should remain in force. However, in order to avoid multiple registrations, economic operators and notified bodies who register in the relevant electronic systems set up at Union level pursuant to this Regulation should be considered to be in compliance with the registration requirements adopted by the Member States pursuant to those provisions.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(97)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">In order to provide for a smooth introduction of the UDI system, the moment of application of the obligation to place the UDI carrier on the label of the device should vary from one to five years after the date of application of this Regulation depending upon the class of the device concerned.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(97)</p>,\n",
       " <p class=\"oj-normal\">In order to provide for a smooth introduction of the UDI system, the moment of application of the obligation to place the UDI carrier on the label of the device should vary from one to five years after the date of application of this Regulation depending upon the class of the device concerned.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(98)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Directives 90/385/EEC and 93/42/EEC should be repealed to ensure that only one set of rules applies to the placing of medical devices on the market and the related aspects covered by this Regulation. Manufacturers' obligations as regards the making available of documentation regarding devices they placed on the market and manufacturers' and Member States' obligations as regards vigilance activities for devices placed on the market pursuant to those Directives should however continue to apply. While it should be left to Member States to decide how to organise vigilance activities, it is desirable for them to have the possibility of reporting incidents related to devices placed on the market pursuant to the Directives using the same tools as those for reporting on devices placed on the market pursuant to this Regulation. It is furthermore appropriate, in order to ensure a smooth transition from the old regime to the new regime, to provide that Commission Regulation (EU) No 207/2012 <a href=\"#ntr28-L_2017117EN.01000101-E0028\" id=\"ntc28-L_2017117EN.01000101-E0028\">(<span class=\"oj-super oj-note-tag\">28</span>)</a> and Commission Regulation (EU) No 722/2012 <a href=\"#ntr29-L_2017117EN.01000101-E0029\" id=\"ntc29-L_2017117EN.01000101-E0029\">(<span class=\"oj-super oj-note-tag\">29</span>)</a> should remain in force and continue to apply unless and until repealed by implementing acts adopted by the Commission pursuant to this Regulation.</p>\n",
       " <p class=\"oj-normal\">Decision 2010/227/EU adopted in implementation of those Directives and Directive 98/79/EC should also remain in force and continue to apply until the date when Eudamed becomes fully functional. Conversely, no such maintenance in force is required for Commission Directives 2003/12/EC <a href=\"#ntr30-L_2017117EN.01000101-E0030\" id=\"ntc30-L_2017117EN.01000101-E0030\">(<span class=\"oj-super oj-note-tag\">30</span>)</a> and 2005/50/EC <a href=\"#ntr31-L_2017117EN.01000101-E0031\" id=\"ntc31-L_2017117EN.01000101-E0031\">(<span class=\"oj-super oj-note-tag\">31</span>)</a> and Commission Implementing Regulation (EU) No 920/2013 <a href=\"#ntr32-L_2017117EN.01000101-E0032\" id=\"ntc32-L_2017117EN.01000101-E0032\">(<span class=\"oj-super oj-note-tag\">32</span>)</a>.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(98)</p>,\n",
       " <p class=\"oj-normal\">Directives 90/385/EEC and 93/42/EEC should be repealed to ensure that only one set of rules applies to the placing of medical devices on the market and the related aspects covered by this Regulation. Manufacturers' obligations as regards the making available of documentation regarding devices they placed on the market and manufacturers' and Member States' obligations as regards vigilance activities for devices placed on the market pursuant to those Directives should however continue to apply. While it should be left to Member States to decide how to organise vigilance activities, it is desirable for them to have the possibility of reporting incidents related to devices placed on the market pursuant to the Directives using the same tools as those for reporting on devices placed on the market pursuant to this Regulation. It is furthermore appropriate, in order to ensure a smooth transition from the old regime to the new regime, to provide that Commission Regulation (EU) No 207/2012 <a href=\"#ntr28-L_2017117EN.01000101-E0028\" id=\"ntc28-L_2017117EN.01000101-E0028\">(<span class=\"oj-super oj-note-tag\">28</span>)</a> and Commission Regulation (EU) No 722/2012 <a href=\"#ntr29-L_2017117EN.01000101-E0029\" id=\"ntc29-L_2017117EN.01000101-E0029\">(<span class=\"oj-super oj-note-tag\">29</span>)</a> should remain in force and continue to apply unless and until repealed by implementing acts adopted by the Commission pursuant to this Regulation.</p>,\n",
       " <p class=\"oj-normal\">Decision 2010/227/EU adopted in implementation of those Directives and Directive 98/79/EC should also remain in force and continue to apply until the date when Eudamed becomes fully functional. Conversely, no such maintenance in force is required for Commission Directives 2003/12/EC <a href=\"#ntr30-L_2017117EN.01000101-E0030\" id=\"ntc30-L_2017117EN.01000101-E0030\">(<span class=\"oj-super oj-note-tag\">30</span>)</a> and 2005/50/EC <a href=\"#ntr31-L_2017117EN.01000101-E0031\" id=\"ntc31-L_2017117EN.01000101-E0031\">(<span class=\"oj-super oj-note-tag\">31</span>)</a> and Commission Implementing Regulation (EU) No 920/2013 <a href=\"#ntr32-L_2017117EN.01000101-E0032\" id=\"ntc32-L_2017117EN.01000101-E0032\">(<span class=\"oj-super oj-note-tag\">32</span>)</a>.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(99)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The requirements of this Regulation should be applicable to all devices placed on the market or put into service from the date of application of this Regulation. However, in order to provide for a smooth transition it should be possible, for a limited period of time from that date, for devices to be placed on the market or put into service by virtue of a valid certificate issued pursuant to Directive 90/385/EEC or pursuant to Directive 93/42/EEC.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(99)</p>,\n",
       " <p class=\"oj-normal\">The requirements of this Regulation should be applicable to all devices placed on the market or put into service from the date of application of this Regulation. However, in order to provide for a smooth transition it should be possible, for a limited period of time from that date, for devices to be placed on the market or put into service by virtue of a valid certificate issued pursuant to Directive 90/385/EEC or pursuant to Directive 93/42/EEC.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(100)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">The European Data Protection Supervisor has given an opinion <a href=\"#ntr33-L_2017117EN.01000101-E0033\" id=\"ntc33-L_2017117EN.01000101-E0033\">(<span class=\"oj-super oj-note-tag\">33</span>)</a> pursuant to Article 28(2) of Regulation (EC) No 45/2001.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(100)</p>,\n",
       " <p class=\"oj-normal\">The European Data Protection Supervisor has given an opinion <a href=\"#ntr33-L_2017117EN.01000101-E0033\" id=\"ntc33-L_2017117EN.01000101-E0033\">(<span class=\"oj-super oj-note-tag\">33</span>)</a> pursuant to Article 28(2) of Regulation (EC) No 45/2001.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(101)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">Since the objectives of this Regulation, namely to ensure the smooth functioning of the internal market as regards medical devices and to ensure high standards of quality and safety for medical devices, thus ensuring a high level of protection of health and safety of patients, users and other persons, cannot be sufficiently achieved by the Member States but can rather, by reason of its scale and effects, be better achieved at Union level, the Union may adopt measures, in accordance with the principle of subsidiarity as set out in Article 5 of the Treaty on European Union. In accordance with the principle of proportionality, as set out in that Article, this Regulation does not go beyond what is necessary in order to achieve those objectives,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(101)</p>,\n",
       " <p class=\"oj-normal\">Since the objectives of this Regulation, namely to ensure the smooth functioning of the internal market as regards medical devices and to ensure high standards of quality and safety for medical devices, thus ensuring a high level of protection of health and safety of patients, users and other persons, cannot be sufficiently achieved by the Member States but can rather, by reason of its scale and effects, be better achieved at Union level, the Union may adopt measures, in accordance with the principle of subsidiarity as set out in Article 5 of the Treaty on European Union. In accordance with the principle of proportionality, as set out in that Article, this Regulation does not go beyond what is necessary in order to achieve those objectives,</p>,\n",
       " <p class=\"oj-normal\">HAVE ADOPTED THIS REGULATION:</p>,\n",
       " <p class=\"oj-ti-section-1\" id=\"d1e1058-1-1\">CHAPTER I</p>,\n",
       " <p class=\"oj-ti-section-2\" id=\"L_2017117EN.01000101-d-001\">\n",
       " <span class=\"oj-bold\">SCOPE AND DEFINITIONS</span>\n",
       " </p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e1066-1-1\">Article 1</p>,\n",
       " <p class=\"oj-sti-art\">Subject matter and scope</p>,\n",
       " <p class=\"oj-normal\">1.   This Regulation lays down rules concerning the placing on the market, making available on the market or putting into service of medical devices for human use and accessories for such devices in the Union. This Regulation also applies to clinical investigations concerning such medical devices and accessories conducted in the Union.</p>,\n",
       " <p class=\"oj-normal\">2.   This Regulation shall also apply, as from the date of application of common specifications adopted pursuant to Article 9, to the groups of products without an intended medical purpose that are listed in Annex XVI, taking into account the state of the art, and in particular existing harmonised standards for analogous devices with a medical purpose, based on similar technology. The common specifications for each of the groups of products listed in Annex XVI shall address, at least, application of risk management as set out in Annex I for the group of products in question and, where necessary, clinical evaluation regarding safety.</p>,\n",
       " <p class=\"oj-normal\">The necessary common specifications shall be adopted by 26 May 2020. They shall apply as from six months after the date of their entry into force or from 26 May 2020, whichever is the latest.</p>,\n",
       " <p class=\"oj-normal\">Notwithstanding Article 122, Member States' measures regarding the qualification of the products covered by Annex XVI as medical devices pursuant to Directive 93/42/EEC shall remain valid until the date of application, as referred to in the first subparagraph, of the relevant common specifications for that group of products.</p>,\n",
       " <p class=\"oj-normal\">This Regulation also applies to clinical investigations conducted in the Union concerning the products referred to in the first subparagraph.</p>,\n",
       " <p class=\"oj-normal\">3.   Devices with both a medical and a non-medical intended purpose shall fulfil cumulatively the requirements applicable to devices with an intended medical purpose and those applicable to devices without an intended medical purpose.</p>,\n",
       " <p class=\"oj-normal\">4.   For the purposes of this Regulation, medical devices, accessories for medical devices, and products listed in Annex XVI to which this Regulation applies pursuant to paragraph 2 shall hereinafter be referred to as ‘devices’.</p>,\n",
       " <p class=\"oj-normal\">5.   Where justified on account of the similarity between a device with an intended medical purpose placed on the market and a product without an intended medical purpose in respect of their characteristics and risks, the Commission is empowered to adopt delegated acts in accordance with Article 115 to amend the list in Annex XVI, by adding new groups of products, in order to protect the health and safety of users or other persons or other aspects of public health.</p>,\n",
       " <p class=\"oj-normal\">6.   This Regulation does not apply to:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">\n",
       " <span class=\"oj-italic\">in vitro</span> diagnostic medical devices covered by Regulation (EU) 2017/746;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">\n",
       " <span class=\"oj-italic\">in vitro</span> diagnostic medical devices covered by Regulation (EU) 2017/746;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">medicinal products as defined in point 2 of Article 1 of Directive 2001/83/EC. In deciding whether a product falls under Directive 2001/83/EC or under this Regulation, particular account shall be taken of the principal mode of action of the product;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">medicinal products as defined in point 2 of Article 1 of Directive 2001/83/EC. In deciding whether a product falls under Directive 2001/83/EC or under this Regulation, particular account shall be taken of the principal mode of action of the product;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">advanced therapy medicinal products covered by Regulation (EC) No 1394/2007;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">advanced therapy medicinal products covered by Regulation (EC) No 1394/2007;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">human blood, blood products, plasma or blood cells of human origin or devices which incorporate, when placed on the market or put into service, such blood products, plasma or cells, except for devices referred to in paragraph 8 of this Article;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">human blood, blood products, plasma or blood cells of human origin or devices which incorporate, when placed on the market or put into service, such blood products, plasma or cells, except for devices referred to in paragraph 8 of this Article;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(e)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">cosmetic products covered by Regulation (EC) No 1223/2009;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(e)</p>,\n",
       " <p class=\"oj-normal\">cosmetic products covered by Regulation (EC) No 1223/2009;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(f)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">transplants, tissues or cells of animal origin, or their derivatives, or products containing or consisting of them; however this Regulation does apply to devices manufactured utilising tissues or cells of animal origin, or their derivatives, which are non-viable or are rendered non-viable;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(f)</p>,\n",
       " <p class=\"oj-normal\">transplants, tissues or cells of animal origin, or their derivatives, or products containing or consisting of them; however this Regulation does apply to devices manufactured utilising tissues or cells of animal origin, or their derivatives, which are non-viable or are rendered non-viable;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(g)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">transplants, tissues or cells of human origin, or their derivatives, covered by Directive 2004/23/EC, or products containing or consisting of them; however this Regulation does apply to devices manufactured utilising derivatives of tissues or cells of human origin which are non-viable or are rendered non-viable;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(g)</p>,\n",
       " <p class=\"oj-normal\">transplants, tissues or cells of human origin, or their derivatives, covered by Directive 2004/23/EC, or products containing or consisting of them; however this Regulation does apply to devices manufactured utilising derivatives of tissues or cells of human origin which are non-viable or are rendered non-viable;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(h)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">products, other than those referred to in points (d), (f) and (g), that contain or consist of viable biological material or viable organisms, including living micro-organisms, bacteria, fungi or viruses in order to achieve or support the intended purpose of the product;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(h)</p>,\n",
       " <p class=\"oj-normal\">products, other than those referred to in points (d), (f) and (g), that contain or consist of viable biological material or viable organisms, including living micro-organisms, bacteria, fungi or viruses in order to achieve or support the intended purpose of the product;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(i)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">food covered by Regulation (EC) No 178/2002.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(i)</p>,\n",
       " <p class=\"oj-normal\">food covered by Regulation (EC) No 178/2002.</p>,\n",
       " <p class=\"oj-normal\">7.   Any device which, when placed on the market or put into service, incorporates as an integral part an <span class=\"oj-italic\">in vitro</span> diagnostic medical device as defined in point 2 of Article 2 of Regulation (EU) 2017/746, shall be governed by this Regulation. The requirements of Regulation (EU) 2017/746 shall apply to the <span class=\"oj-italic\">in vitro</span> diagnostic medical device part of the device.</p>,\n",
       " <p class=\"oj-normal\">8.   Any device which, when placed on the market or put into service, incorporates, as an integral part, a substance which, if used separately, would be considered to be a medicinal product as defined in point 2 of Article 1 of Directive 2001/83/EC, including a medicinal product derived from human blood or human plasma as defined in point 10 of Article 1 of that Directive, and that has an action ancillary to that of the device, shall be assessed and authorised in accordance with this Regulation.</p>,\n",
       " <p class=\"oj-normal\">However, if the action of that substance is principal and not ancillary to that of the device, the integral product shall be governed by Directive 2001/83/EC or Regulation (EC) No 726/2004 of the European Parliament and of the Council <a href=\"#ntr34-L_2017117EN.01000101-E0034\" id=\"ntc34-L_2017117EN.01000101-E0034\">(<span class=\"oj-super oj-note-tag\">34</span>)</a>, as applicable. In that case, the relevant general safety and performance requirements set out in Annex I to this Regulation shall apply as far as the safety and performance of the device part are concerned.</p>,\n",
       " <p class=\"oj-normal\">9.   Any device which is intended to administer a medicinal product as defined in point 2 of Article 1 of Directive 2001/83/EC shall be governed by this Regulation, without prejudice to the provisions of that Directive and of Regulation (EC) No 726/2004 with regard to the medicinal product.</p>,\n",
       " <p class=\"oj-normal\">However, if the device intended to administer a medicinal product and the medicinal product are placed on the market in such a way that they form a single integral product which is intended exclusively for use in the given combination and which is not reusable, that single integral product shall be governed by Directive 2001/83/EC or Regulation (EC) No 726/2004, as applicable. In that case, the relevant general safety and performance requirements set out in Annex I to this Regulation shall apply as far as the safety and performance of the device part of the single integral product are concerned.</p>,\n",
       " <p class=\"oj-normal\">10.   Any device which, when placed on the market or put into service, incorporates, as an integral part, non-viable tissues or cells of human origin or their derivatives that have an action ancillary to that of the device shall be assessed and authorised in accordance with this Regulation. In that case, the provisions for donation, procurement and testing laid down in Directive 2004/23/EC shall apply.</p>,\n",
       " <p class=\"oj-normal\">However, if the action of those tissues or cells or their derivatives is principal and not ancillary to that of the device and the product is not governed by Regulation (EC) No 1394/2007, the product shall be governed by Directive 2004/23/EC. In that case, the relevant general safety and performance requirements set out in Annex I to this Regulation shall apply as far as the safety and performance of the device part are concerned.</p>,\n",
       " <p class=\"oj-normal\">11.   This Regulation is specific Union legislation within the meaning of Article 2(3) of Directive 2014/30/EU.</p>,\n",
       " <p class=\"oj-normal\">12.   Devices that are also machinery within the meaning of point (a) of the second paragraph of Article 2 of Directive 2006/42/EC of the European Parliament and of the Council <a href=\"#ntr35-L_2017117EN.01000101-E0035\" id=\"ntc35-L_2017117EN.01000101-E0035\">(<span class=\"oj-super oj-note-tag\">35</span>)</a> shall, where a hazard relevant under that Directive exists, also meet the essential health and safety requirements set out in Annex I to that Directive to the extent to which those requirements are more specific than the general safety and performance requirements set out in Chapter II of Annex I to this Regulation.</p>,\n",
       " <p class=\"oj-normal\">13.   This Regulation shall not affect the application of Directive 2013/59/Euratom.</p>,\n",
       " <p class=\"oj-normal\">14.   This Regulation shall not affect the right of a Member State to restrict the use of any specific type of device in relation to aspects not covered by this Regulation.</p>,\n",
       " <p class=\"oj-normal\">15.   This Regulation shall not affect national law concerning the organisation, delivery or financing of health services and medical care, such as the requirement that certain devices may only be supplied on a medical prescription, the requirement that only certain health professionals or healthcare institutions may dispense or use certain devices or that their use be accompanied by specific professional counselling.</p>,\n",
       " <p class=\"oj-normal\">16.   Nothing in this Regulation shall restrict the freedom of the press or the freedom of expression in the media in so far as those freedoms are guaranteed in the Union and in the Member States, in particular under Article 11 of the Charter of Fundamental Rights of the European Union.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e1258-1-1\">Article 2</p>,\n",
       " <p class=\"oj-sti-art\">Definitions</p>,\n",
       " <p class=\"oj-normal\">For the purposes of this Regulation, the following definitions apply:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(1)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘medical device’ means any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the following specific medical purposes:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury or disability,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">investigation, replacement or modification of the anatomy or of a physiological or pathological process or state,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">providing information by means of <span class=\"oj-italic\">in vitro</span> examination of specimens derived from the human body, including organ, blood and tissue donations,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <p class=\"oj-normal\">and which does not achieve its principal intended action by pharmacological, immunological or metabolic means, in or on the human body, but which may be assisted in its function by such means.</p>\n",
       " <p class=\"oj-normal\">The following products shall also be deemed to be medical devices:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">devices for the control or support of conception;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">products specifically intended for the cleaning, disinfection or sterilisation of devices as referred to in Article 1(4) and of those referred to in the first paragraph of this point.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(1)</p>,\n",
       " <p class=\"oj-normal\">‘medical device’ means any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the following specific medical purposes:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury or disability,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury or disability,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">investigation, replacement or modification of the anatomy or of a physiological or pathological process or state,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">investigation, replacement or modification of the anatomy or of a physiological or pathological process or state,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">providing information by means of <span class=\"oj-italic\">in vitro</span> examination of specimens derived from the human body, including organ, blood and tissue donations,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">providing information by means of <span class=\"oj-italic\">in vitro</span> examination of specimens derived from the human body, including organ, blood and tissue donations,</p>,\n",
       " <p class=\"oj-normal\">and which does not achieve its principal intended action by pharmacological, immunological or metabolic means, in or on the human body, but which may be assisted in its function by such means.</p>,\n",
       " <p class=\"oj-normal\">The following products shall also be deemed to be medical devices:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">devices for the control or support of conception;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">devices for the control or support of conception;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">products specifically intended for the cleaning, disinfection or sterilisation of devices as referred to in Article 1(4) and of those referred to in the first paragraph of this point.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">products specifically intended for the cleaning, disinfection or sterilisation of devices as referred to in Article 1(4) and of those referred to in the first paragraph of this point.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(2)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘accessory for a medical device’ means an article which, whilst not being itself a medical device, is intended by its manufacturer to be used together with one or several particular medical device(s) to specifically enable the medical device(s) to be used in accordance with its/their intended purpose(s) or to specifically and directly assist the medical functionality of the medical device(s) in terms of its/their intended purpose(s);</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(2)</p>,\n",
       " <p class=\"oj-normal\">‘accessory for a medical device’ means an article which, whilst not being itself a medical device, is intended by its manufacturer to be used together with one or several particular medical device(s) to specifically enable the medical device(s) to be used in accordance with its/their intended purpose(s) or to specifically and directly assist the medical functionality of the medical device(s) in terms of its/their intended purpose(s);</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(3)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘custom-made device’ means any device specifically made in accordance with a written prescription of any person authorised by national law by virtue of that person's professional qualifications which gives, under that person's responsibility, specific design characteristics, and is intended for the sole use of a particular patient exclusively to meet their individual conditions and needs.</p>\n",
       " <p class=\"oj-normal\">However, mass-produced devices which need to be adapted to meet the specific requirements of any professional user and devices which are mass-produced by means of industrial manufacturing processes in accordance with the written prescriptions of any authorised person shall not be considered to be custom-made devices;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(3)</p>,\n",
       " <p class=\"oj-normal\">‘custom-made device’ means any device specifically made in accordance with a written prescription of any person authorised by national law by virtue of that person's professional qualifications which gives, under that person's responsibility, specific design characteristics, and is intended for the sole use of a particular patient exclusively to meet their individual conditions and needs.</p>,\n",
       " <p class=\"oj-normal\">However, mass-produced devices which need to be adapted to meet the specific requirements of any professional user and devices which are mass-produced by means of industrial manufacturing processes in accordance with the written prescriptions of any authorised person shall not be considered to be custom-made devices;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(4)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘active device’ means any device, the operation of which depends on a source of energy other than that generated by the human body for that purpose, or by gravity, and which acts by changing the density of or converting that energy. Devices intended to transmit energy, substances or other elements between an active device and the patient, without any significant change, shall not be deemed to be active devices.</p>\n",
       " <p class=\"oj-normal\">Software shall also be deemed to be an active device;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(4)</p>,\n",
       " <p class=\"oj-normal\">‘active device’ means any device, the operation of which depends on a source of energy other than that generated by the human body for that purpose, or by gravity, and which acts by changing the density of or converting that energy. Devices intended to transmit energy, substances or other elements between an active device and the patient, without any significant change, shall not be deemed to be active devices.</p>,\n",
       " <p class=\"oj-normal\">Software shall also be deemed to be an active device;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(5)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘implantable device’ means any device, including those that are partially or wholly absorbed, which is intended:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">to be totally introduced into the human body, or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">to replace an epithelial surface or the surface of the eye,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <p class=\"oj-normal\">by clinical intervention and which is intended to remain in place after the procedure.</p>\n",
       " <p class=\"oj-normal\">Any device intended to be partially introduced into the human body by clinical intervention and intended to remain in place after the procedure for at least 30 days shall also be deemed to be an implantable device;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(5)</p>,\n",
       " <p class=\"oj-normal\">‘implantable device’ means any device, including those that are partially or wholly absorbed, which is intended:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">to be totally introduced into the human body, or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">to be totally introduced into the human body, or</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">to replace an epithelial surface or the surface of the eye,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">to replace an epithelial surface or the surface of the eye,</p>,\n",
       " <p class=\"oj-normal\">by clinical intervention and which is intended to remain in place after the procedure.</p>,\n",
       " <p class=\"oj-normal\">Any device intended to be partially introduced into the human body by clinical intervention and intended to remain in place after the procedure for at least 30 days shall also be deemed to be an implantable device;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(6)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘invasive device’ means any device which, in whole or in part, penetrates inside the body, either through a body orifice or through the surface of the body;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(6)</p>,\n",
       " <p class=\"oj-normal\">‘invasive device’ means any device which, in whole or in part, penetrates inside the body, either through a body orifice or through the surface of the body;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(7)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘generic device group’ means a set of devices having the same or similar intended purposes or a commonality of technology allowing them to be classified in a generic manner not reflecting specific characteristics;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(7)</p>,\n",
       " <p class=\"oj-normal\">‘generic device group’ means a set of devices having the same or similar intended purposes or a commonality of technology allowing them to be classified in a generic manner not reflecting specific characteristics;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(8)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘single-use device’ means a device that is intended to be used on one individual during a single procedure;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(8)</p>,\n",
       " <p class=\"oj-normal\">‘single-use device’ means a device that is intended to be used on one individual during a single procedure;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(9)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘falsified device’ means any device with a false presentation of its identity and/or of its source and/or its CE marking certificates or documents relating to CE marking procedures. This definition does not include unintentional non-compliance and is without prejudice to infringements of intellectual property rights;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(9)</p>,\n",
       " <p class=\"oj-normal\">‘falsified device’ means any device with a false presentation of its identity and/or of its source and/or its CE marking certificates or documents relating to CE marking procedures. This definition does not include unintentional non-compliance and is without prejudice to infringements of intellectual property rights;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(10)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘procedure pack’ means a combination of products packaged together and placed on the market with the purpose of being used for a specific medical purpose;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(10)</p>,\n",
       " <p class=\"oj-normal\">‘procedure pack’ means a combination of products packaged together and placed on the market with the purpose of being used for a specific medical purpose;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(11)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘system’ means a combination of products, either packaged together or not, which are intended to be inter-connected or combined to achieve a specific medical purpose;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(11)</p>,\n",
       " <p class=\"oj-normal\">‘system’ means a combination of products, either packaged together or not, which are intended to be inter-connected or combined to achieve a specific medical purpose;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(12)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘intended purpose’ means the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(12)</p>,\n",
       " <p class=\"oj-normal\">‘intended purpose’ means the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(13)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘label’ means the written, printed or graphic information appearing either on the device itself, or on the packaging of each unit or on the packaging of multiple devices;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(13)</p>,\n",
       " <p class=\"oj-normal\">‘label’ means the written, printed or graphic information appearing either on the device itself, or on the packaging of each unit or on the packaging of multiple devices;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(14)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘instructions for use’ means the information provided by the manufacturer to inform the user of a device's intended purpose and proper use and of any precautions to be taken;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(14)</p>,\n",
       " <p class=\"oj-normal\">‘instructions for use’ means the information provided by the manufacturer to inform the user of a device's intended purpose and proper use and of any precautions to be taken;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(15)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘Unique Device Identifier’ (‘UDI’) means a series of numeric or alphanumeric characters that is created through internationally accepted device identification and coding standards and that allows unambiguous identification of specific devices on the market;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(15)</p>,\n",
       " <p class=\"oj-normal\">‘Unique Device Identifier’ (‘UDI’) means a series of numeric or alphanumeric characters that is created through internationally accepted device identification and coding standards and that allows unambiguous identification of specific devices on the market;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(16)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘non-viable’ means having no potential for metabolism or multiplication;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(16)</p>,\n",
       " <p class=\"oj-normal\">‘non-viable’ means having no potential for metabolism or multiplication;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(17)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘derivative’ means a ‘non-cellular substance’ extracted from human or animal tissue or cells through a manufacturing process. The final substance used for manufacturing of the device in this case does not contain any cells or tissues;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(17)</p>,\n",
       " <p class=\"oj-normal\">‘derivative’ means a ‘non-cellular substance’ extracted from human or animal tissue or cells through a manufacturing process. The final substance used for manufacturing of the device in this case does not contain any cells or tissues;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(18)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘nanomaterial’ means a natural, incidental or manufactured material containing particles in an unbound state or as an aggregate or as an agglomerate and where, for 50 % or more of the particles in the number size distribution, one or more external dimensions is in the size range 1-100 nm;</p>\n",
       " <p class=\"oj-normal\">Fullerenes, graphene flakes and single-wall carbon nanotubes with one or more external dimensions below 1 nm shall also be deemed to be nanomaterials;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(18)</p>,\n",
       " <p class=\"oj-normal\">‘nanomaterial’ means a natural, incidental or manufactured material containing particles in an unbound state or as an aggregate or as an agglomerate and where, for 50 % or more of the particles in the number size distribution, one or more external dimensions is in the size range 1-100 nm;</p>,\n",
       " <p class=\"oj-normal\">Fullerenes, graphene flakes and single-wall carbon nanotubes with one or more external dimensions below 1 nm shall also be deemed to be nanomaterials;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(19)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘particle’, for the purposes of the definition of nanomaterial in point (18), means a minute piece of matter with defined physical boundaries;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(19)</p>,\n",
       " <p class=\"oj-normal\">‘particle’, for the purposes of the definition of nanomaterial in point (18), means a minute piece of matter with defined physical boundaries;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(20)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘agglomerate’, for the purposes of the definition of nanomaterial in point (18), means a collection of weakly bound particles or aggregates where the resulting external surface area is similar to the sum of the surface areas of the individual components;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(20)</p>,\n",
       " <p class=\"oj-normal\">‘agglomerate’, for the purposes of the definition of nanomaterial in point (18), means a collection of weakly bound particles or aggregates where the resulting external surface area is similar to the sum of the surface areas of the individual components;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(21)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘aggregate’, for the purposes of the definition of nanomaterial in point (18), means a particle comprising of strongly bound or fused particles;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(21)</p>,\n",
       " <p class=\"oj-normal\">‘aggregate’, for the purposes of the definition of nanomaterial in point (18), means a particle comprising of strongly bound or fused particles;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(22)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘performance’ means the ability of a device to achieve its intended purpose as stated by the manufacturer;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(22)</p>,\n",
       " <p class=\"oj-normal\">‘performance’ means the ability of a device to achieve its intended purpose as stated by the manufacturer;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(23)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘risk’ means the combination of the probability of occurrence of harm and the severity of that harm;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(23)</p>,\n",
       " <p class=\"oj-normal\">‘risk’ means the combination of the probability of occurrence of harm and the severity of that harm;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(24)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘benefit-risk determination’ means the analysis of all assessments of benefit and risk of possible relevance for the use of the device for the intended purpose, when used in accordance with the intended purpose given by the manufacturer;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(24)</p>,\n",
       " <p class=\"oj-normal\">‘benefit-risk determination’ means the analysis of all assessments of benefit and risk of possible relevance for the use of the device for the intended purpose, when used in accordance with the intended purpose given by the manufacturer;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(25)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘compatibility’ is the ability of a device, including software, when used together with one or more other devices in accordance with its intended purpose, to:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">perform without losing or compromising the ability to perform as intended, and/or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">integrate and/or operate without the need for modification or adaption of any part of the combined devices, and/or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">be used together without conflict/interference or adverse reaction.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(25)</p>,\n",
       " <p class=\"oj-normal\">‘compatibility’ is the ability of a device, including software, when used together with one or more other devices in accordance with its intended purpose, to:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">perform without losing or compromising the ability to perform as intended, and/or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">perform without losing or compromising the ability to perform as intended, and/or</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">integrate and/or operate without the need for modification or adaption of any part of the combined devices, and/or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">integrate and/or operate without the need for modification or adaption of any part of the combined devices, and/or</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">be used together without conflict/interference or adverse reaction.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">be used together without conflict/interference or adverse reaction.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(26)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘interoperability’ is the ability of two or more devices, including software, from the same manufacturer or from different manufacturers, to:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">exchange information and use the information that has been exchanged for the correct execution of a specified function without changing the content of the data, and/or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">communicate with each other, and/or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">work together as intended.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(26)</p>,\n",
       " <p class=\"oj-normal\">‘interoperability’ is the ability of two or more devices, including software, from the same manufacturer or from different manufacturers, to:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">exchange information and use the information that has been exchanged for the correct execution of a specified function without changing the content of the data, and/or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">exchange information and use the information that has been exchanged for the correct execution of a specified function without changing the content of the data, and/or</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">communicate with each other, and/or</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">communicate with each other, and/or</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">work together as intended.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">work together as intended.</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(27)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘making available on the market’ means any supply of a device, other than an investigational device, for distribution, consumption or use on the Union market in the course of a commercial activity, whether in return for payment or free of charge;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(27)</p>,\n",
       " <p class=\"oj-normal\">‘making available on the market’ means any supply of a device, other than an investigational device, for distribution, consumption or use on the Union market in the course of a commercial activity, whether in return for payment or free of charge;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(28)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘placing on the market’ means the first making available of a device, other than an investigational device, on the Union market;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(28)</p>,\n",
       " <p class=\"oj-normal\">‘placing on the market’ means the first making available of a device, other than an investigational device, on the Union market;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(29)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘putting into service’ means the stage at which a device, other than an investigational device, has been made available to the final user as being ready for use on the Union market for the first time for its intended purpose;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(29)</p>,\n",
       " <p class=\"oj-normal\">‘putting into service’ means the stage at which a device, other than an investigational device, has been made available to the final user as being ready for use on the Union market for the first time for its intended purpose;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(30)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘manufacturer’ means a natural or legal person who manufactures or fully refurbishes a device or has a device designed, manufactured or fully refurbished, and markets that device under its name or trademark;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(30)</p>,\n",
       " <p class=\"oj-normal\">‘manufacturer’ means a natural or legal person who manufactures or fully refurbishes a device or has a device designed, manufactured or fully refurbished, and markets that device under its name or trademark;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(31)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘fully refurbishing’, for the purposes of the definition of manufacturer, means the complete rebuilding of a device already placed on the market or put into service, or the making of a new device from used devices, to bring it into conformity with this Regulation, combined with the assignment of a new lifetime to the refurbished device;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(31)</p>,\n",
       " <p class=\"oj-normal\">‘fully refurbishing’, for the purposes of the definition of manufacturer, means the complete rebuilding of a device already placed on the market or put into service, or the making of a new device from used devices, to bring it into conformity with this Regulation, combined with the assignment of a new lifetime to the refurbished device;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(32)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘authorised representative’ means any natural or legal person established within the Union who has received and accepted a written mandate from a manufacturer, located outside the Union, to act on the manufacturer's behalf in relation to specified tasks with regard to the latter's obligations under this Regulation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(32)</p>,\n",
       " <p class=\"oj-normal\">‘authorised representative’ means any natural or legal person established within the Union who has received and accepted a written mandate from a manufacturer, located outside the Union, to act on the manufacturer's behalf in relation to specified tasks with regard to the latter's obligations under this Regulation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(33)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘importer’ means any natural or legal person established within the Union that places a device from a third country on the Union market;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(33)</p>,\n",
       " <p class=\"oj-normal\">‘importer’ means any natural or legal person established within the Union that places a device from a third country on the Union market;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(34)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘distributor’ means any natural or legal person in the supply chain, other than the manufacturer or the importer, that makes a device available on the market, up until the point of putting into service;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(34)</p>,\n",
       " <p class=\"oj-normal\">‘distributor’ means any natural or legal person in the supply chain, other than the manufacturer or the importer, that makes a device available on the market, up until the point of putting into service;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(35)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘economic operator’ means a manufacturer, an authorised representative, an importer, a distributor or the person referred to in Article 22(1) and 22(3);</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(35)</p>,\n",
       " <p class=\"oj-normal\">‘economic operator’ means a manufacturer, an authorised representative, an importer, a distributor or the person referred to in Article 22(1) and 22(3);</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(36)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘health institution’ means an organisation the primary purpose of which is the care or treatment of patients or the promotion of public health;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(36)</p>,\n",
       " <p class=\"oj-normal\">‘health institution’ means an organisation the primary purpose of which is the care or treatment of patients or the promotion of public health;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(37)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘user’ means any healthcare professional or lay person who uses a device;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(37)</p>,\n",
       " <p class=\"oj-normal\">‘user’ means any healthcare professional or lay person who uses a device;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(38)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘lay person’ means an individual who does not have formal education in a relevant field of healthcare or medical discipline;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(38)</p>,\n",
       " <p class=\"oj-normal\">‘lay person’ means an individual who does not have formal education in a relevant field of healthcare or medical discipline;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(39)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘reprocessing’ means a process carried out on a used device in order to allow its safe reuse including cleaning, disinfection, sterilisation and related procedures, as well as testing and restoring the technical and functional safety of the used device;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(39)</p>,\n",
       " <p class=\"oj-normal\">‘reprocessing’ means a process carried out on a used device in order to allow its safe reuse including cleaning, disinfection, sterilisation and related procedures, as well as testing and restoring the technical and functional safety of the used device;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(40)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘conformity assessment’ means the process demonstrating whether the requirements of this Regulation relating to a device have been fulfilled;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(40)</p>,\n",
       " <p class=\"oj-normal\">‘conformity assessment’ means the process demonstrating whether the requirements of this Regulation relating to a device have been fulfilled;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(41)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘conformity assessment body’ means a body that performs third-party conformity assessment activities including calibration, testing, certification and inspection;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(41)</p>,\n",
       " <p class=\"oj-normal\">‘conformity assessment body’ means a body that performs third-party conformity assessment activities including calibration, testing, certification and inspection;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(42)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘notified body’ means a conformity assessment body designated in accordance with this Regulation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(42)</p>,\n",
       " <p class=\"oj-normal\">‘notified body’ means a conformity assessment body designated in accordance with this Regulation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(43)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘CE marking of conformity’ or ‘CE marking’ means a marking by which a manufacturer indicates that a device is in conformity with the applicable requirements set out in this Regulation and other applicable Union harmonisation legislation providing for its affixing;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(43)</p>,\n",
       " <p class=\"oj-normal\">‘CE marking of conformity’ or ‘CE marking’ means a marking by which a manufacturer indicates that a device is in conformity with the applicable requirements set out in this Regulation and other applicable Union harmonisation legislation providing for its affixing;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(44)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘clinical evaluation’ means a systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device in order to verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(44)</p>,\n",
       " <p class=\"oj-normal\">‘clinical evaluation’ means a systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device in order to verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(45)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘clinical investigation’ means any systematic investigation involving one or more human subjects, undertaken to assess the safety or performance of a device;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(45)</p>,\n",
       " <p class=\"oj-normal\">‘clinical investigation’ means any systematic investigation involving one or more human subjects, undertaken to assess the safety or performance of a device;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(46)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘investigational device’ means a device that is assessed in a clinical investigation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(46)</p>,\n",
       " <p class=\"oj-normal\">‘investigational device’ means a device that is assessed in a clinical investigation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(47)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘clinical investigation plan’ means a document that describes the rationale, objectives, design, methodology, monitoring, statistical considerations, organisation and conduct of a clinical investigation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(47)</p>,\n",
       " <p class=\"oj-normal\">‘clinical investigation plan’ means a document that describes the rationale, objectives, design, methodology, monitoring, statistical considerations, organisation and conduct of a clinical investigation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(48)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘clinical data’ means information concerning safety or performance that is generated from the use of a device and is sourced from the following:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">clinical investigation(s) of the device concerned,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">clinical investigation(s) or other studies reported in scientific literature, of a device for which equivalence to the device in question can be demonstrated,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">reports published in peer reviewed scientific literature on other clinical experience of either the device in question or a device for which equivalence to the device in question can be demonstrated,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">clinically relevant information coming from post-market surveillance, in particular the post-market clinical follow-up;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(48)</p>,\n",
       " <p class=\"oj-normal\">‘clinical data’ means information concerning safety or performance that is generated from the use of a device and is sourced from the following:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">clinical investigation(s) of the device concerned,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">clinical investigation(s) of the device concerned,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">clinical investigation(s) or other studies reported in scientific literature, of a device for which equivalence to the device in question can be demonstrated,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">clinical investigation(s) or other studies reported in scientific literature, of a device for which equivalence to the device in question can be demonstrated,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">reports published in peer reviewed scientific literature on other clinical experience of either the device in question or a device for which equivalence to the device in question can be demonstrated,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">reports published in peer reviewed scientific literature on other clinical experience of either the device in question or a device for which equivalence to the device in question can be demonstrated,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">—</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">clinically relevant information coming from post-market surveillance, in particular the post-market clinical follow-up;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">—</p>,\n",
       " <p class=\"oj-normal\">clinically relevant information coming from post-market surveillance, in particular the post-market clinical follow-up;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(49)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘sponsor’ means any individual, company, institution or organisation which takes responsibility for the initiation, for the management and setting up of the financing of the clinical investigation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(49)</p>,\n",
       " <p class=\"oj-normal\">‘sponsor’ means any individual, company, institution or organisation which takes responsibility for the initiation, for the management and setting up of the financing of the clinical investigation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(50)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘subject’ means an individual who participates in a clinical investigation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(50)</p>,\n",
       " <p class=\"oj-normal\">‘subject’ means an individual who participates in a clinical investigation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(51)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘clinical evidence’ means clinical data and clinical evaluation results pertaining to a device of a sufficient amount and quality to allow a qualified assessment of whether the device is safe and achieves the intended clinical benefit(s), when used as intended by the manufacturer;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(51)</p>,\n",
       " <p class=\"oj-normal\">‘clinical evidence’ means clinical data and clinical evaluation results pertaining to a device of a sufficient amount and quality to allow a qualified assessment of whether the device is safe and achieves the intended clinical benefit(s), when used as intended by the manufacturer;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(52)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘clinical performance’ means the ability of a device, resulting from any direct or indirect medical effects which stem from its technical or functional characteristics, including diagnostic characteristics, to achieve its intended purpose as claimed by the manufacturer, thereby leading to a clinical benefit for patients, when used as intended by the manufacturer;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(52)</p>,\n",
       " <p class=\"oj-normal\">‘clinical performance’ means the ability of a device, resulting from any direct or indirect medical effects which stem from its technical or functional characteristics, including diagnostic characteristics, to achieve its intended purpose as claimed by the manufacturer, thereby leading to a clinical benefit for patients, when used as intended by the manufacturer;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(53)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘clinical benefit’ means the positive impact of a device on the health of an individual, expressed in terms of a meaningful, measurable, patient-relevant clinical outcome(s), including outcome(s) related to diagnosis, or a positive impact on patient management or public health;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(53)</p>,\n",
       " <p class=\"oj-normal\">‘clinical benefit’ means the positive impact of a device on the health of an individual, expressed in terms of a meaningful, measurable, patient-relevant clinical outcome(s), including outcome(s) related to diagnosis, or a positive impact on patient management or public health;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(54)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘investigator’ means an individual responsible for the conduct of a clinical investigation at a clinical investigation site;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(54)</p>,\n",
       " <p class=\"oj-normal\">‘investigator’ means an individual responsible for the conduct of a clinical investigation at a clinical investigation site;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(55)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘informed consent’ means a subject's free and voluntary expression of his or her willingness to participate in a particular clinical investigation, after having been informed of all aspects of the clinical investigation that are relevant to the subject's decision to participate or, in the case of minors and of incapacitated subjects, an authorisation or agreement from their legally designated representative to include them in the clinical investigation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(55)</p>,\n",
       " <p class=\"oj-normal\">‘informed consent’ means a subject's free and voluntary expression of his or her willingness to participate in a particular clinical investigation, after having been informed of all aspects of the clinical investigation that are relevant to the subject's decision to participate or, in the case of minors and of incapacitated subjects, an authorisation or agreement from their legally designated representative to include them in the clinical investigation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(56)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘ethics committee’ means an independent body established in a Member State in accordance with the law of that Member State and empowered to give opinions for the purposes of this Regulation, taking into account the views of laypersons, in particular patients or patients' organisations;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(56)</p>,\n",
       " <p class=\"oj-normal\">‘ethics committee’ means an independent body established in a Member State in accordance with the law of that Member State and empowered to give opinions for the purposes of this Regulation, taking into account the views of laypersons, in particular patients or patients' organisations;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(57)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘adverse event’ means any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in subjects, users or other persons, in the context of a clinical investigation, whether or not related to the investigational device;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(57)</p>,\n",
       " <p class=\"oj-normal\">‘adverse event’ means any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in subjects, users or other persons, in the context of a clinical investigation, whether or not related to the investigational device;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(58)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘serious adverse event’ means any adverse event that led to any of the following:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">death,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">serious deterioration in the health of the subject, that resulted in any of the following:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(i)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">life-threatening illness or injury,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(ii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">permanent impairment of a body structure or a body function,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(iii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">hospitalisation or prolongation of patient hospitalisation,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(iv)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(v)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">chronic disease,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">foetal distress, foetal death or a congenital physical or mental impairment or birth defect;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(58)</p>,\n",
       " <p class=\"oj-normal\">‘serious adverse event’ means any adverse event that led to any of the following:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">death,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">death,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">serious deterioration in the health of the subject, that resulted in any of the following:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(i)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">life-threatening illness or injury,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(ii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">permanent impairment of a body structure or a body function,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(iii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">hospitalisation or prolongation of patient hospitalisation,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(iv)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(v)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">chronic disease,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">serious deterioration in the health of the subject, that resulted in any of the following:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(i)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">life-threatening illness or injury,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(i)</p>,\n",
       " <p class=\"oj-normal\">life-threatening illness or injury,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(ii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">permanent impairment of a body structure or a body function,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(ii)</p>,\n",
       " <p class=\"oj-normal\">permanent impairment of a body structure or a body function,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(iii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">hospitalisation or prolongation of patient hospitalisation,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(iii)</p>,\n",
       " <p class=\"oj-normal\">hospitalisation or prolongation of patient hospitalisation,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(iv)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(iv)</p>,\n",
       " <p class=\"oj-normal\">medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(v)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">chronic disease,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(v)</p>,\n",
       " <p class=\"oj-normal\">chronic disease,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">foetal distress, foetal death or a congenital physical or mental impairment or birth defect;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">foetal distress, foetal death or a congenital physical or mental impairment or birth defect;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(59)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘device deficiency’ means any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in information supplied by the manufacturer;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(59)</p>,\n",
       " <p class=\"oj-normal\">‘device deficiency’ means any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in information supplied by the manufacturer;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(60)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘post-market surveillance’ means all activities carried out by manufacturers in cooperation with other economic operators to institute and keep up to date a systematic procedure to proactively collect and review experience gained from devices they place on the market, make available on the market or put into service for the purpose of identifying any need to immediately apply any necessary corrective or preventive actions;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(60)</p>,\n",
       " <p class=\"oj-normal\">‘post-market surveillance’ means all activities carried out by manufacturers in cooperation with other economic operators to institute and keep up to date a systematic procedure to proactively collect and review experience gained from devices they place on the market, make available on the market or put into service for the purpose of identifying any need to immediately apply any necessary corrective or preventive actions;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(61)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘market surveillance’ means the activities carried out and measures taken by competent authorities to check and ensure that devices comply with the requirements set out in the relevant Union harmonisation legislation and do not endanger health, safety or any other aspect of public interest protection;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(61)</p>,\n",
       " <p class=\"oj-normal\">‘market surveillance’ means the activities carried out and measures taken by competent authorities to check and ensure that devices comply with the requirements set out in the relevant Union harmonisation legislation and do not endanger health, safety or any other aspect of public interest protection;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(62)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘recall’ means any measure aimed at achieving the return of a device that has already been made available to the end user;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(62)</p>,\n",
       " <p class=\"oj-normal\">‘recall’ means any measure aimed at achieving the return of a device that has already been made available to the end user;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(63)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘withdrawal’ means any measure aimed at preventing a device in the supply chain from being further made available on the market;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(63)</p>,\n",
       " <p class=\"oj-normal\">‘withdrawal’ means any measure aimed at preventing a device in the supply chain from being further made available on the market;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(64)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘incident’ means any malfunction or deterioration in the characteristics or performance of a device made available on the market, including use-error due to ergonomic features, as well as any inadequacy in the information supplied by the manufacturer and any undesirable side-effect;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(64)</p>,\n",
       " <p class=\"oj-normal\">‘incident’ means any malfunction or deterioration in the characteristics or performance of a device made available on the market, including use-error due to ergonomic features, as well as any inadequacy in the information supplied by the manufacturer and any undesirable side-effect;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(65)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘serious incident’ means any incident that directly or indirectly led, might have led or might lead to any of the following:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the death of a patient, user or other person,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the temporary or permanent serious deterioration of a patient's, user's or other person's state of health,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">a serious public health threat;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(65)</p>,\n",
       " <p class=\"oj-normal\">‘serious incident’ means any incident that directly or indirectly led, might have led or might lead to any of the following:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the death of a patient, user or other person,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">the death of a patient, user or other person,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the temporary or permanent serious deterioration of a patient's, user's or other person's state of health,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">the temporary or permanent serious deterioration of a patient's, user's or other person's state of health,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">a serious public health threat;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">a serious public health threat;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(66)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘serious public health threat’ means an event which could result in imminent risk of death, serious deterioration in a person's state of health, or serious illness, that may require prompt remedial action, and that may cause significant morbidity or mortality in humans, or that is unusual or unexpected for the given place and time;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(66)</p>,\n",
       " <p class=\"oj-normal\">‘serious public health threat’ means an event which could result in imminent risk of death, serious deterioration in a person's state of health, or serious illness, that may require prompt remedial action, and that may cause significant morbidity or mortality in humans, or that is unusual or unexpected for the given place and time;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(67)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘corrective action’ means action taken to eliminate the cause of a potential or actual non-conformity or other undesirable situation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(67)</p>,\n",
       " <p class=\"oj-normal\">‘corrective action’ means action taken to eliminate the cause of a potential or actual non-conformity or other undesirable situation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(68)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘field safety corrective action’ means corrective action taken by a manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident in relation to a device made available on the market;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(68)</p>,\n",
       " <p class=\"oj-normal\">‘field safety corrective action’ means corrective action taken by a manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident in relation to a device made available on the market;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(69)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘field safety notice’ means a communication sent by a manufacturer to users or customers in relation to a field safety corrective action;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(69)</p>,\n",
       " <p class=\"oj-normal\">‘field safety notice’ means a communication sent by a manufacturer to users or customers in relation to a field safety corrective action;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(70)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘harmonised standard’ means a European standard as defined in point (1)(c) of Article 2 of Regulation (EU) No 1025/2012;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(70)</p>,\n",
       " <p class=\"oj-normal\">‘harmonised standard’ means a European standard as defined in point (1)(c) of Article 2 of Regulation (EU) No 1025/2012;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(71)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">‘common specifications’ (CS) means a set of technical and/or clinical requirements, other than a standard, that provides a means of complying with the legal obligations applicable to a device, process or system.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(71)</p>,\n",
       " <p class=\"oj-normal\">‘common specifications’ (CS) means a set of technical and/or clinical requirements, other than a standard, that provides a means of complying with the legal obligations applicable to a device, process or system.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2097-1-1\">Article 3</p>,\n",
       " <p class=\"oj-sti-art\">Amendment of certain definitions</p>,\n",
       " <p class=\"oj-normal\">The Commission is empowered to adopt delegated acts in accordance with Article 115 in order to amend the definition of nanomaterial set out in point (18) and the related definitions in points (19), (20) and (21) of Article 2 in the light of technical and scientific progress and taking into account definitions agreed at Union and international level.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2104-1-1\">Article 4</p>,\n",
       " <p class=\"oj-sti-art\">Regulatory status of products</p>,\n",
       " <p class=\"oj-normal\">1.   Without prejudice to Article 2(2) of Directive 2001/83/EC, upon a duly substantiated request of a Member State, the Commission shall, after consulting the Medical Device Coordination Group established under Article 103 of this Regulation (‘MDCG’), by means of implementing acts, determine whether or not a specific product, or category or group of products, falls within the definitions of ‘medical device’ or ‘accessory for a medical device’. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 114(3) of this Regulation.</p>,\n",
       " <p class=\"oj-normal\">2.   The Commission may also, on its own initiative, after consulting the MDCG, decide, by means of implementing acts, on the issues referred to in paragraph 1 of this Article. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 114(3).</p>,\n",
       " <p class=\"oj-normal\">3.   The Commission shall ensure that Member States share expertise in the fields of medical devices, <span class=\"oj-italic\">in vitro</span> diagnostic medical devices, medicinal products, human tissues and cells, cosmetics, biocides, food and, if necessary, other products, in order to determine the appropriate regulatory status of a product, or category or group of products.</p>,\n",
       " <p class=\"oj-normal\">4.   When deliberating on the possible regulatory status as a device of products involving medicinal products, human tissues and cells, biocides or food products, the Commission shall ensure an appropriate level of consultation of the European Medicines Agency (EMA), the European Chemicals Agency (ECHA) and the European Food Safety Authority (EFSA), as relevant.</p>,\n",
       " <p class=\"oj-ti-section-1\" id=\"d1e2146-1-1\">CHAPTER II</p>,\n",
       " <p class=\"oj-ti-section-2\" id=\"L_2017117EN.01000101-d-002\">\n",
       " <span class=\"oj-bold\">MAKING AVAILABLE ON THE MARKET AND PUTTING INTO SERVICE OF DEVICES, OBLIGATIONS OF ECONOMIC OPERATORS, REPROCESSING, CE MARKING, FREE MOVEMENT</span>\n",
       " </p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2154-1-1\">Article 5</p>,\n",
       " <p class=\"oj-sti-art\">Placing on the market and putting into service</p>,\n",
       " <p class=\"oj-normal\">1.   A device may be placed on the market or put into service only if it complies with this Regulation when duly supplied and properly installed, maintained and used in accordance with its intended purpose.</p>,\n",
       " <p class=\"oj-normal\">2.   A device shall meet the general safety and performance requirements set out in Annex I which apply to it, taking into account its intended purpose.</p>,\n",
       " <p class=\"oj-normal\">3.   Demonstration of conformity with the general safety and performance requirements shall include a clinical evaluation in accordance with Article 61.</p>,\n",
       " <p class=\"oj-normal\">4.   Devices that are manufactured and used within health institutions shall be considered as having been put into service.</p>,\n",
       " <p class=\"oj-normal\">5.   With the exception of the relevant general safety and performance requirements set out in Annex I, the requirements of this Regulation shall not apply to devices, manufactured and used only within health institutions established in the Union, provided that all of the following conditions are met:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the devices are not transferred to another legal entity,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">the devices are not transferred to another legal entity,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">manufacture and use of the devices occur under appropriate quality management systems,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">manufacture and use of the devices occur under appropriate quality management systems,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the health institution justifies in its documentation that the target patient group's specific needs cannot be met, or cannot be met at the appropriate level of performance by an equivalent device available on the market,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">the health institution justifies in its documentation that the target patient group's specific needs cannot be met, or cannot be met at the appropriate level of performance by an equivalent device available on the market,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the health institution provides information upon request on the use of such devices to its competent authority, which shall include a justification of their manufacturing, modification and use;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">the health institution provides information upon request on the use of such devices to its competent authority, which shall include a justification of their manufacturing, modification and use;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(e)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the health institution draws up a declaration which it shall make publicly available, including:</p>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(i)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the name and address of the manufacturing health institution;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(ii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the details necessary to identify the devices;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(iii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">a declaration that the devices meet the general safety and performance requirements set out in Annex I to this Regulation and, where applicable, information on which requirements are not fully met with a reasoned justification therefor,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(e)</p>,\n",
       " <p class=\"oj-normal\">the health institution draws up a declaration which it shall make publicly available, including:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(i)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the name and address of the manufacturing health institution;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(i)</p>,\n",
       " <p class=\"oj-normal\">the name and address of the manufacturing health institution;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(ii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the details necessary to identify the devices;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(ii)</p>,\n",
       " <p class=\"oj-normal\">the details necessary to identify the devices;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(iii)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">a declaration that the devices meet the general safety and performance requirements set out in Annex I to this Regulation and, where applicable, information on which requirements are not fully met with a reasoned justification therefor,</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(iii)</p>,\n",
       " <p class=\"oj-normal\">a declaration that the devices meet the general safety and performance requirements set out in Annex I to this Regulation and, where applicable, information on which requirements are not fully met with a reasoned justification therefor,</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(f)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the health institution draws up documentation that makes it possible to have an understanding of the manufacturing facility, the manufacturing process, the design and performance data of the devices, including the intended purpose, and that is sufficiently detailed to enable the competent authority to ascertain that the general safety and performance requirements set out in Annex I to this Regulation are met;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(f)</p>,\n",
       " <p class=\"oj-normal\">the health institution draws up documentation that makes it possible to have an understanding of the manufacturing facility, the manufacturing process, the design and performance data of the devices, including the intended purpose, and that is sufficiently detailed to enable the competent authority to ascertain that the general safety and performance requirements set out in Annex I to this Regulation are met;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(g)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the health institution takes all necessary measures to ensure that all devices are manufactured in accordance with the documentation referred to in point (f), and</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(g)</p>,\n",
       " <p class=\"oj-normal\">the health institution takes all necessary measures to ensure that all devices are manufactured in accordance with the documentation referred to in point (f), and</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(h)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the health institution reviews experience gained from clinical use of the devices and takes all necessary corrective actions.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(h)</p>,\n",
       " <p class=\"oj-normal\">the health institution reviews experience gained from clinical use of the devices and takes all necessary corrective actions.</p>,\n",
       " <p class=\"oj-normal\">Member States may require that such health institutions submit to the competent authority any further relevant information about such devices which have been manufactured and used on their territory. Member States shall retain the right to restrict the manufacture and the use of any specific type of such devices and shall be permitted access to inspect the activities of the health institutions.</p>,\n",
       " <p class=\"oj-normal\">This paragraph shall not apply to devices that are manufactured on an industrial scale.</p>,\n",
       " <p class=\"oj-normal\">6.   In order to ensure the uniform application of Annex I, the Commission may adopt implementing acts to the extent necessary to resolve issues of divergent interpretation and of practical application. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 114(3).</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2263-1-1\">Article 6</p>,\n",
       " <p class=\"oj-sti-art\">Distance sales</p>,\n",
       " <p class=\"oj-normal\">1.   A device offered by means of information society services, as defined in point (b) of Article 1(1) of Directive (EU) 2015/1535, to a natural or legal person established in the Union shall comply with this Regulation.</p>,\n",
       " <p class=\"oj-normal\">2.   Without prejudice to national law regarding the exercise of the medical profession, a device that is not placed on the market but used in the context of a commercial activity, whether in return for payment or free of charge, for the provision of a diagnostic or therapeutic service offered by means of information society services as defined in point (b) of Article 1(1) of Directive (EU) 2015/1535 or by other means of communication, directly or through intermediaries, to a natural or legal person established in the Union shall comply with this Regulation.</p>,\n",
       " <p class=\"oj-normal\">3.   Upon request by a competent authority, any natural or legal person offering a device in accordance with paragraph 1 or providing a service in accordance with paragraph 2 shall make available a copy of the EU declaration of conformity of the device concerned.</p>,\n",
       " <p class=\"oj-normal\">4.   A Member State may, on grounds of protection of public health, require a provider of information society services, as defined in point (b) of Article 1(1) of Directive (EU) 2015/1535, to cease its activity.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2288-1-1\">Article 7</p>,\n",
       " <p class=\"oj-sti-art\">Claims</p>,\n",
       " <p class=\"oj-normal\">In the labelling, instructions for use, making available, putting into service and advertising of devices, it shall be prohibited to use text, names, trademarks, pictures and figurative or other signs that may mislead the user or the patient with regard to the device's intended purpose, safety and performance by:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">ascribing functions and properties to the device which the device does not have;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">ascribing functions and properties to the device which the device does not have;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">creating a false impression regarding treatment or diagnosis, functions or properties which the device does not have;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">creating a false impression regarding treatment or diagnosis, functions or properties which the device does not have;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">failing to inform the user or the patient of a likely risk associated with the use of the device in line with its intended purpose;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">failing to inform the user or the patient of a likely risk associated with the use of the device in line with its intended purpose;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">suggesting uses for the device other than those stated to form part of the intended purpose for which the conformity assessment was carried out.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">suggesting uses for the device other than those stated to form part of the intended purpose for which the conformity assessment was carried out.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2321-1-1\">Article 8</p>,\n",
       " <p class=\"oj-sti-art\">Use of harmonised standards</p>,\n",
       " <p class=\"oj-normal\">1.   Devices that are in conformity with the relevant harmonised standards, or the relevant parts of those standards, the references of which have been published in the <span class=\"oj-italic\">Official Journal of the European Union</span>, shall be presumed to be in conformity with the requirements of this Regulation covered by those standards or parts thereof.</p>,\n",
       " <p class=\"oj-normal\">The first subparagraph shall also apply to system or process requirements to be fulfilled in accordance with this Regulation by economic operators or sponsors, including those relating to quality management systems, risk management, post-market surveillance systems, clinical investigations, clinical evaluation or post-market clinical follow-up (‘PMCF’).</p>,\n",
       " <p class=\"oj-normal\">References in this Regulation to harmonised standards shall be understood as meaning harmonised standards the references of which have been published in the <span class=\"oj-italic\">Official Journal of the European Union</span>.</p>,\n",
       " <p class=\"oj-normal\">2.   References in this Regulation to harmonised standards shall also include the monographs of the European Pharmacopoeia adopted in accordance with the Convention on the Elaboration of a European Pharmacopoeia, in particular on surgical sutures and on interaction between medicinal products and materials used in devices containing such medicinal products, provided that references to those monographs have been published in the <span class=\"oj-italic\">Official Journal of the European Union</span>.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2353-1-1\">Article 9</p>,\n",
       " <p class=\"oj-sti-art\">Common specifications</p>,\n",
       " <p class=\"oj-normal\">1.   Without prejudice to Article 1(2) and 17(5) and the deadline laid down in those provisions, where no harmonised standards exist or where relevant harmonised standards are not sufficient, or where there is a need to address public health concerns, the Commission, after having consulted the MDCG, may, by means of implementing acts, adopt common specifications (CS) in respect of the general safety and performance requirements set out in Annex I, the technical documentation set out in Annexes II and III, the clinical evaluation and post-market clinical follow-up set out in Annex XIV or the requirements regarding clinical investigation set out in Annex XV. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 114(3).</p>,\n",
       " <p class=\"oj-normal\">2.   Devices that are in conformity with the CS referred to in paragraph 1 shall be presumed to be in conformity with the requirements of this Regulation covered by those CS or the relevant parts of those CS.</p>,\n",
       " <p class=\"oj-normal\">3.   Manufacturers shall comply with the CS referred to in paragraph 1 unless they can duly justify that they have adopted solutions that ensure a level of safety and performance that is at least equivalent thereto.</p>,\n",
       " <p class=\"oj-normal\">4.   Notwithstanding paragraph 3, manufacturers of products listed in Annex XVI shall comply with the relevant CS for those products.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2378-1-1\">Article 10</p>,\n",
       " <p class=\"oj-sti-art\">General obligations of manufacturers</p>,\n",
       " <p class=\"oj-normal\">1.   When placing their devices on the market or putting them into service, manufacturers shall ensure that they have been designed and manufactured in accordance with the requirements of this Regulation.</p>,\n",
       " <p class=\"oj-normal\">2.   Manufacturers shall establish, document, implement and maintain a system for risk management as described in Section 3 of Annex I.</p>,\n",
       " <p class=\"oj-normal\">3.   Manufacturers shall conduct a clinical evaluation in accordance with the requirements set out in Article 61 and Annex XIV, including a PMCF.</p>,\n",
       " <p class=\"oj-normal\">4.   Manufacturers of devices other than custom-made devices shall draw up and keep up to date technical documentation for those devices. The technical documentation shall be such as to allow the conformity of the device with the requirements of this Regulation to be assessed. The technical documentation shall include the elements set out in Annexes II and III.</p>,\n",
       " <p class=\"oj-normal\">The Commission is empowered to adopt delegated acts in accordance with Article 115 amending, in the light of technical progress, the Annexes II and III.</p>,\n",
       " <p class=\"oj-normal\">5.   Manufacturers of custom-made devices shall draw up, keep up to date and keep available for competent authorities documentation in accordance with Section 2 of Annex XIII.</p>,\n",
       " <p class=\"oj-normal\">6.   Where compliance with the applicable requirements has been demonstrated following the applicable conformity assessment procedure, manufacturers of devices, other than custom-made or investigational devices, shall draw up an EU declaration of conformity in accordance with Article 19, and affix the CE marking of conformity in accordance with Article 20.</p>,\n",
       " <p class=\"oj-normal\">7.   Manufacturers shall comply with the obligations relating to the UDI system referred to in Article 27 and with the registration obligations referred to in Articles 29 and 31.</p>,\n",
       " <p class=\"oj-normal\">8.   Manufacturers shall keep the technical documentation, the EU declaration of conformity and, if applicable, a copy of any relevant certificate, including any amendments and supplements, issued in accordance with Article 56, available for the competent authorities for a period of at least 10 years after the last device covered by the EU declaration of conformity has been placed on the market. In the case of implantable devices, the period shall be at least 15 years after the last device has been placed on the market.</p>,\n",
       " <p class=\"oj-normal\">Upon request by a competent authority, the manufacturer shall, as indicated therein, provide that technical documentation in its entirety or a summary thereof.</p>,\n",
       " <p class=\"oj-normal\">A manufacturer with a registered place of business outside the Union shall, in order to allow its authorised representative to fulfil the tasks mentioned in Article 11(3), ensure that the authorised representative has the necessary documentation permanently available.</p>,\n",
       " <p class=\"oj-normal\">9.   Manufacturers shall ensure that procedures are in place to keep series production in conformity with the requirements of this Regulation. Changes in device design or characteristics and changes in the harmonised standards or CS by reference to which the conformity of a device is declared shall be adequately taken into account in a timely manner. Manufacturers of devices, other than investigational devices, shall establish, document, implement, maintain, keep up to date and continually improve a quality management system that shall ensure compliance with this Regulation in the most effective manner and in a manner that is proportionate to the risk class and the type of device.</p>,\n",
       " <p class=\"oj-normal\">The quality management system shall cover all parts and elements of a manufacturer's organisation dealing with the quality of processes, procedures and devices. It shall govern the structure, responsibilities, procedures, processes and management resources required to implement the principles and actions necessary to achieve compliance with the provisions of this Regulation.</p>,\n",
       " <p class=\"oj-normal\">The quality management system shall address at least the following aspects:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">a strategy for regulatory compliance, including compliance with conformity assessment procedures and procedures for management of modifications to the devices covered by the system;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">a strategy for regulatory compliance, including compliance with conformity assessment procedures and procedures for management of modifications to the devices covered by the system;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">identification of applicable general safety and performance requirements and exploration of options to address those requirements;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">identification of applicable general safety and performance requirements and exploration of options to address those requirements;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">responsibility of the management;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">responsibility of the management;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">resource management, including selection and control of suppliers and sub-contractors;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">resource management, including selection and control of suppliers and sub-contractors;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(e)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">risk management as set out in in Section 3 of Annex I;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(e)</p>,\n",
       " <p class=\"oj-normal\">risk management as set out in in Section 3 of Annex I;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(f)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">clinical evaluation in accordance with Article 61 and Annex XIV, including PMCF;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(f)</p>,\n",
       " <p class=\"oj-normal\">clinical evaluation in accordance with Article 61 and Annex XIV, including PMCF;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(g)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">product realisation, including planning, design, development, production and service provision;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(g)</p>,\n",
       " <p class=\"oj-normal\">product realisation, including planning, design, development, production and service provision;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(h)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">verification of the UDI assignments made in accordance with Article 27(3) to all relevant devices and ensuring consistency and validity of information provided in accordance with Article 29;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(h)</p>,\n",
       " <p class=\"oj-normal\">verification of the UDI assignments made in accordance with Article 27(3) to all relevant devices and ensuring consistency and validity of information provided in accordance with Article 29;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(i)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">setting-up, implementation and maintenance of a post-market surveillance system, in accordance with Article 83;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(i)</p>,\n",
       " <p class=\"oj-normal\">setting-up, implementation and maintenance of a post-market surveillance system, in accordance with Article 83;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(j)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">handling communication with competent authorities, notified bodies, other economic operators, customers and/or other stakeholders;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(j)</p>,\n",
       " <p class=\"oj-normal\">handling communication with competent authorities, notified bodies, other economic operators, customers and/or other stakeholders;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(k)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">processes for reporting of serious incidents and field safety corrective actions in the context of vigilance;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(k)</p>,\n",
       " <p class=\"oj-normal\">processes for reporting of serious incidents and field safety corrective actions in the context of vigilance;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(l)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">management of corrective and preventive actions and verification of their effectiveness;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(l)</p>,\n",
       " <p class=\"oj-normal\">management of corrective and preventive actions and verification of their effectiveness;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(m)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">processes for monitoring and measurement of output, data analysis and product improvement.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(m)</p>,\n",
       " <p class=\"oj-normal\">processes for monitoring and measurement of output, data analysis and product improvement.</p>,\n",
       " <p class=\"oj-normal\">10.   Manufacturers of devices shall implement and keep up to date the post-market surveillance system in accordance with Article 83.</p>,\n",
       " <p class=\"oj-normal\">11.   Manufacturers shall ensure that the device is accompanied by the information set out in Section 23 of Annex I in an official Union language(s) determined by the Member State in which the device is made available to the user or patient. The particulars on the label shall be indelible, easily legible and clearly comprehensible to the intended user or patient.</p>,\n",
       " <p class=\"oj-normal\">12.   Manufacturers who consider or have reason to believe that a device which they have placed on the market or put into service is not in conformity with this Regulation shall immediately take the necessary corrective action to bring that device into conformity, to withdraw it or to recall it, as appropriate. They shall inform the distributors of the device in question and, where applicable, the authorised representative and importers accordingly.</p>,\n",
       " <p class=\"oj-normal\">Where the device presents a serious risk, manufacturers shall immediately inform the competent authorities of the Member States in which they made the device available and, where applicable, the notified body that issued a certificate for the device in accordance with Article 56, in particular, of the non-compliance and of any corrective action taken.</p>,\n",
       " <p class=\"oj-normal\">13.   Manufacturers shall have a system for recording and reporting of incidents and field safety corrective actions as described in Articles 87 and 88.</p>,\n",
       " <p class=\"oj-normal\">14.   Manufacturers shall, upon request by a competent authority, provide it with all the information and documentation necessary to demonstrate the conformity of the device, in an official Union language determined by the Member State concerned. The competent authority of the Member State in which the manufacturer has its registered place of business may require that the manufacturer provide samples of the device free of charge or, where that is impracticable, grant access to the device. Manufacturers shall cooperate with a competent authority, at its request, on any corrective action taken to eliminate or, if that is not possible, mitigate the risks posed by devices which they have placed on the market or put into service.</p>,\n",
       " <p class=\"oj-normal\">If the manufacturer fails to cooperate or the information and documentation provided is incomplete or incorrect, the competent authority may, in order to ensure the protection of public health and patient safety, take all appropriate measures to prohibit or restrict the device's being made available on its national market, to withdraw the device from that market or to recall it until the manufacturer cooperates or provides complete and correct information.</p>,\n",
       " <p class=\"oj-normal\">If a competent authority considers or has reason to believe that a device has caused damage, it shall, upon request, facilitate the provision of the information and documentation referred to in the first subparagraph to the potentially injured patient or user and, as appropriate, the patient's or user's successor in title, the patient's or user's health insurance company or other third parties affected by the damage caused to the patient or user, without prejudice to data protection rules and, unless there is an overriding public interest in disclosure, without prejudice to the protection of intellectual property rights.</p>,\n",
       " <p class=\"oj-normal\">The competent authority need not comply with the obligation laid down in the third subparagraph where disclosure of the information and documentation referred to in the first subparagraph is ordinarily dealt with in the context of legal proceedings.</p>,\n",
       " <p class=\"oj-normal\">15.   Where manufacturers have their devices designed or manufactured by another legal or natural person the information on the identity of that person shall be part of the information to be submitted in accordance with Article 30(1).</p>,\n",
       " <p class=\"oj-normal\">16.   Natural or legal persons may claim compensation for damage caused by a defective device in accordance with applicable Union and national law.</p>,\n",
       " <p class=\"oj-normal\">Manufacturers shall, in a manner that is proportionate to the risk class, type of device and the size of the enterprise, have measures in place to provide sufficient financial coverage in respect of their potential liability under Directive 85/374/EEC, without prejudice to more protective measures under national law.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2565-1-1\">Article 11</p>,\n",
       " <p class=\"oj-sti-art\">Authorised representative</p>,\n",
       " <p class=\"oj-normal\">1.   Where the manufacturer of a device is not established in a Member State, the device may only be placed on the Union market if the manufacturer designates a sole authorised representative.</p>,\n",
       " <p class=\"oj-normal\">2.   The designation shall constitute the authorised representative's mandate, it shall be valid only when accepted in writing by the authorised representative and shall be effective at least for all devices of the same generic device group.</p>,\n",
       " <p class=\"oj-normal\">3.   The authorised representative shall perform the tasks specified in the mandate agreed between it and the manufacturer. The authorised representative shall provide a copy of the mandate to the competent authority, upon request.</p>,\n",
       " <p class=\"oj-normal\">The mandate shall require, and the manufacturer shall enable, the authorised representative to perform at least the following tasks in relation to the devices that it covers:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">verify that the EU declaration of conformity and technical documentation have been drawn up and, where applicable, that an appropriate conformity assessment procedure has been carried out by the manufacturer;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">verify that the EU declaration of conformity and technical documentation have been drawn up and, where applicable, that an appropriate conformity assessment procedure has been carried out by the manufacturer;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">keep available a copy of the technical documentation, the EU declaration of conformity and, if applicable, a copy of the relevant certificate, including any amendments and supplements, issued in accordance with Article 56, at the disposal of competent authorities for the period referred to in Article 10(8);</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">keep available a copy of the technical documentation, the EU declaration of conformity and, if applicable, a copy of the relevant certificate, including any amendments and supplements, issued in accordance with Article 56, at the disposal of competent authorities for the period referred to in Article 10(8);</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">comply with the registration obligations laid down in Article 31 and verify that the manufacturer has complied with the registration obligations laid down in Articles 27 and 29;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">comply with the registration obligations laid down in Article 31 and verify that the manufacturer has complied with the registration obligations laid down in Articles 27 and 29;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">in response to a request from a competent authority, provide that competent authority with all the information and documentation necessary to demonstrate the conformity of a device, in an official Union language determined by the Member State concerned;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">in response to a request from a competent authority, provide that competent authority with all the information and documentation necessary to demonstrate the conformity of a device, in an official Union language determined by the Member State concerned;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(e)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">forward to the manufacturer any request by a competent authority of the Member State in which the authorised representative has its registered place of business for samples, or access to a device and verify that the competent authority receives the samples or is given access to the device;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(e)</p>,\n",
       " <p class=\"oj-normal\">forward to the manufacturer any request by a competent authority of the Member State in which the authorised representative has its registered place of business for samples, or access to a device and verify that the competent authority receives the samples or is given access to the device;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(f)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">cooperate with the competent authorities on any preventive or corrective action taken to eliminate or, if that is not possible, mitigate the risks posed by devices;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(f)</p>,\n",
       " <p class=\"oj-normal\">cooperate with the competent authorities on any preventive or corrective action taken to eliminate or, if that is not possible, mitigate the risks posed by devices;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(g)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">immediately inform the manufacturer about complaints and reports from healthcare professionals, patients and users about suspected incidents related to a device for which they have been designated;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(g)</p>,\n",
       " <p class=\"oj-normal\">immediately inform the manufacturer about complaints and reports from healthcare professionals, patients and users about suspected incidents related to a device for which they have been designated;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(h)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">terminate the mandate if the manufacturer acts contrary to its obligations under this Regulation.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(h)</p>,\n",
       " <p class=\"oj-normal\">terminate the mandate if the manufacturer acts contrary to its obligations under this Regulation.</p>,\n",
       " <p class=\"oj-normal\">4.   The mandate referred to in paragraph 3 of this Article shall not delegate the manufacturer's obligations laid down in Article 10(1), (2), (3), (4), (6), (7), (9), (10), (11) and (12).</p>,\n",
       " <p class=\"oj-normal\">5.   Without prejudice to paragraph 4 of this Article, where the manufacturer is not established in a Member State and has not complied with the obligations laid down in Article 10, the authorised representative shall be legally liable for defective devices on the same basis as, and jointly and severally with, the manufacturer.</p>,\n",
       " <p class=\"oj-normal\">6.   An authorised representative who terminates its mandate on the ground referred to in point (h) of paragraph 3 shall immediately inform the competent authority of the Member State in which it is established and, where applicable, the notified body that was involved in the conformity assessment for the device of the termination of the mandate and the reasons therefor.</p>,\n",
       " <p class=\"oj-normal\">7.   Any reference in this Regulation to the competent authority of the Member State in which the manufacturer has its registered place of business shall be understood as a reference to the competent authority of the Member State in which the authorised representative, designated by a manufacturer referred to in paragraph 1, has its registered place of business.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2657-1-1\">Article 12</p>,\n",
       " <p class=\"oj-sti-art\">Change of authorised representative</p>,\n",
       " <p class=\"oj-normal\">The detailed arrangements for a change of authorised representative shall be clearly defined in an agreement between the manufacturer, where practicable the outgoing authorised representative, and the incoming authorised representative. That agreement shall address at least the following aspects:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the date of termination of the mandate of the outgoing authorised representative and date of beginning of the mandate of the incoming authorised representative;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">the date of termination of the mandate of the outgoing authorised representative and date of beginning of the mandate of the incoming authorised representative;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the date until which the outgoing authorised representative may be indicated in the information supplied by the manufacturer, including any promotional material;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">the date until which the outgoing authorised representative may be indicated in the information supplied by the manufacturer, including any promotional material;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the transfer of documents, including confidentiality aspects and property rights;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">the transfer of documents, including confidentiality aspects and property rights;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the obligation of the outgoing authorised representative after the end of the mandate to forward to the manufacturer or incoming authorised representative any complaints or reports from healthcare professionals, patients or users about suspected incidents related to a device for which it had been designated as authorised representative.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">the obligation of the outgoing authorised representative after the end of the mandate to forward to the manufacturer or incoming authorised representative any complaints or reports from healthcare professionals, patients or users about suspected incidents related to a device for which it had been designated as authorised representative.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2690-1-1\">Article 13</p>,\n",
       " <p class=\"oj-sti-art\">General obligations of importers</p>,\n",
       " <p class=\"oj-normal\">1.   Importers shall place on the Union market only devices that are in conformity with this Regulation.</p>,\n",
       " <p class=\"oj-normal\">2.   In order to place a device on the market, importers shall verify that:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the device has been CE marked and that the EU declaration of conformity of the device has been drawn up;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">the device has been CE marked and that the EU declaration of conformity of the device has been drawn up;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">a manufacturer is identified and that an authorised representative in accordance with Article 11 has been designated by the manufacturer;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">a manufacturer is identified and that an authorised representative in accordance with Article 11 has been designated by the manufacturer;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the device is labelled in accordance with this Regulation and accompanied by the required instructions for use;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">the device is labelled in accordance with this Regulation and accompanied by the required instructions for use;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">where applicable, a UDI has been assigned by the manufacturer in accordance with Article 27.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">where applicable, a UDI has been assigned by the manufacturer in accordance with Article 27.</p>,\n",
       " <p class=\"oj-normal\">Where an importer considers or has reason to believe that a device is not in conformity with the requirements of this Regulation, it shall not place the device on the market until it has been brought into conformity and shall inform the manufacturer and the manufacturer's authorised representative. Where the importer considers or has reason to believe that the device presents a serious risk or is a falsified device, it shall also inform the competent authority of the Member State in which the importer is established.</p>,\n",
       " <p class=\"oj-normal\">3.   Importers shall indicate on the device or on its packaging or in a document accompanying the device their name, registered trade name or registered trade mark, their registered place of business and the address at which they can be contacted, so that their location can be established. They shall ensure that any additional label does not obscure any information on the label provided by the manufacturer.</p>,\n",
       " <p class=\"oj-normal\">4.   Importers shall verify that the device is registered in the electronic system in accordance with Article 29. Importers shall add their details to the registration in accordance with Article 31.</p>,\n",
       " <p class=\"oj-normal\">5.   Importers shall ensure that, while a device is under their responsibility, storage or transport conditions do not jeopardise its compliance with the general safety and performance requirements set out in Annex I and shall comply with the conditions set by the manufacturer, where available.</p>,\n",
       " <p class=\"oj-normal\">6.   Importers shall keep a register of complaints, of non-conforming devices and of recalls and withdrawals, and provide the manufacturer, authorised representative and distributors with any information requested by them, in order to allow them to investigate complaints.</p>,\n",
       " <p class=\"oj-normal\">7.   Importers who consider or have reason to believe that a device which they have placed on the market is not in conformity with this Regulation shall immediately inform the manufacturer and its authorised representative. Importers shall co-operate with the manufacturer, the manufacturer's authorised representative and the competent authorities to ensure that the necessary corrective action to bring that device into conformity, to withdraw or recall it is taken. Where the device presents a serious risk, they shall also immediately inform the competent authorities of the Member States in which they made the device available and, if applicable, the notified body that issued a certificate in accordance with Article 56 for the device in question, giving details, in particular, of the non-compliance and of any corrective action taken.</p>,\n",
       " <p class=\"oj-normal\">8.   Importers who have received complaints or reports from healthcare professionals, patients or users about suspected incidents related to a device which they have placed on the market shall immediately forward this information to the manufacturer and its authorised representative.</p>,\n",
       " <p class=\"oj-normal\">9.   Importers shall, for the period referred to in Article 10(8), keep a copy of the EU declaration of conformity and, if applicable, a copy of any relevant certificate, including any amendments and supplements, issued in accordance with Article 56.</p>,\n",
       " <p class=\"oj-normal\">10.   Importers shall cooperate with competent authorities, at the latters' request, on any action taken to eliminate or, if that is not possible, mitigate the risks posed by devices which they have placed on the market. Importers, upon request by a competent authority of the Member State in which the importer has its registered place of business, shall provide samples of the device free of charge or, where that is impracticable, grant access to the device.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2774-1-1\">Article 14</p>,\n",
       " <p class=\"oj-sti-art\">General obligations of distributors</p>,\n",
       " <p class=\"oj-normal\">1.   When making a device available on the market, distributors shall, in the context of their activities, act with due care in relation to the requirements applicable.</p>,\n",
       " <p class=\"oj-normal\">2.   Before making a device available on the market, distributors shall verify that all of the following requirements are met:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the device has been CE marked and that the EU declaration of conformity of the device has been drawn up;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">the device has been CE marked and that the EU declaration of conformity of the device has been drawn up;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the device is accompanied by the information to be supplied by the manufacturer in accordance with Article 10(11);</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">the device is accompanied by the information to be supplied by the manufacturer in accordance with Article 10(11);</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">for imported devices, the importer has complied with the requirements set out in Article 13(3);</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">for imported devices, the importer has complied with the requirements set out in Article 13(3);</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">that, where applicable, a UDI has been assigned by the manufacturer.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">that, where applicable, a UDI has been assigned by the manufacturer.</p>,\n",
       " <p class=\"oj-normal\">In order to meet the requirements referred to in points (a), (b) and (d) of the first subparagraph the distributor may apply a sampling method that is representative of the devices supplied by that distributor.</p>,\n",
       " <p class=\"oj-normal\">Where a distributor considers or has reason to believe that a device is not in conformity with the requirements of this Regulation, it shall not make the device available on the market until it has been brought into conformity, and shall inform the manufacturer and, where applicable, the manufacturer's authorised representative, and the importer. Where the distributor considers or has reason to believe that the device presents a serious risk or is a falsified device, it shall also inform the competent authority of the Member State in which it is established.</p>,\n",
       " <p class=\"oj-normal\">3.   Distributors shall ensure that, while the device is under their responsibility, storage or transport conditions comply with the conditions set by the manufacturer.</p>,\n",
       " <p class=\"oj-normal\">4.   Distributors that consider or have reason to believe that a device which they have made available on the market is not in conformity with this Regulation shall immediately inform the manufacturer and, where applicable, the manufacturer's authorised representative and the importer. Distributors shall co-operate with the manufacturer and, where applicable, the manufacturer's authorised representative, and the importer, and with competent authorities to ensure that the necessary corrective action to bring that device into conformity, to withdraw or to recall it, as appropriate, is taken. Where the distributor considers or has reason to believe that the device presents a serious risk, it shall also immediately inform the competent authorities of the Member States in which it made the device available, giving details, in particular, of the non-compliance and of any corrective action taken.</p>,\n",
       " <p class=\"oj-normal\">5.   Distributors that have received complaints or reports from healthcare professionals, patients or users about suspected incidents related to a device they have made available, shall immediately forward this information to the manufacturer and, where applicable, the manufacturer's authorised representative, and the importer. They shall keep a register of complaints, of non-conforming devices and of recalls and withdrawals, and keep the manufacturer and, where available, the authorised representative and the importer informed of such monitoring and provide them with any information upon their request.</p>,\n",
       " <p class=\"oj-normal\">6.   Distributors shall, upon request by a competent authority, provide it with all the information and documentation that is at their disposal and is necessary to demonstrate the conformity of a device.</p>,\n",
       " <p class=\"oj-normal\">Distributors shall be considered to have fulfilled the obligation referred to in the first subparagraph when the manufacturer or, where applicable, the authorised representative for the device in question provides the required information. Distributors shall cooperate with competent authorities, at their request, on any action taken to eliminate the risks posed by devices which they have made available on the market. Distributors, upon request by a competent authority, shall provide free samples of the device or, where that is impracticable, grant access to the device.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2842-1-1\">Article 15</p>,\n",
       " <p class=\"oj-sti-art\">Person responsible for regulatory compliance</p>,\n",
       " <p class=\"oj-normal\">1.   Manufacturers shall have available within their organisation at least one person responsible for regulatory compliance who possesses the requisite expertise in the field of medical devices. The requisite expertise shall be demonstrated by either of the following qualifications:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">a diploma, certificate or other evidence of formal qualification, awarded on completion of a university degree or of a course of study recognised as equivalent by the Member State concerned, in law, medicine, pharmacy, engineering or another relevant scientific discipline, and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">a diploma, certificate or other evidence of formal qualification, awarded on completion of a university degree or of a course of study recognised as equivalent by the Member State concerned, in law, medicine, pharmacy, engineering or another relevant scientific discipline, and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">four years of professional experience in regulatory affairs or in quality management systems relating to medical devices.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">four years of professional experience in regulatory affairs or in quality management systems relating to medical devices.</p>,\n",
       " <p class=\"oj-normal\">Without prejudice to national provisions regarding professional qualifications, manufacturers of custom-made devices may demonstrate the requisite expertise referred to in the first subparagraph by having at least two years of professional experience within a relevant field of manufacturing.</p>,\n",
       " <p class=\"oj-normal\">2.   Micro and small enterprises within the meaning of Commission Recommendation 2003/361/EC <a href=\"#ntr36-L_2017117EN.01000101-E0036\" id=\"ntc36-L_2017117EN.01000101-E0036\">(<span class=\"oj-super oj-note-tag\">36</span>)</a> shall not be required to have the person responsible for regulatory compliance within their organisation but shall have such person permanently and continuously at their disposal.</p>,\n",
       " <p class=\"oj-normal\">3.   The person responsible for regulatory compliance shall at least be responsible for ensuring that:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the conformity of the devices is appropriately checked, in accordance with the quality management system under which the devices are manufactured, before a device is released;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">the conformity of the devices is appropriately checked, in accordance with the quality management system under which the devices are manufactured, before a device is released;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the technical documentation and the EU declaration of conformity are drawn up and kept up-to-date;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">the technical documentation and the EU declaration of conformity are drawn up and kept up-to-date;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the post-market surveillance obligations are complied with in accordance with Article 10(10);</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">the post-market surveillance obligations are complied with in accordance with Article 10(10);</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(d)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">the reporting obligations referred to in Articles 87 to 91 are fulfilled;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(d)</p>,\n",
       " <p class=\"oj-normal\">the reporting obligations referred to in Articles 87 to 91 are fulfilled;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(e)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">in the case of investigational devices, the statement referred to in Section 4.1 of Chapter II of Annex XV is issued.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(e)</p>,\n",
       " <p class=\"oj-normal\">in the case of investigational devices, the statement referred to in Section 4.1 of Chapter II of Annex XV is issued.</p>,\n",
       " <p class=\"oj-normal\">4.   If a number of persons are jointly responsible for regulatory compliance in accordance with paragraphs 1, 2 and 3, their respective areas of responsibility shall be stipulated in writing.</p>,\n",
       " <p class=\"oj-normal\">5.   The person responsible for regulatory compliance shall suffer no disadvantage within the manufacturer's organisation in relation to the proper fulfilment of his or her duties, regardless of whether or not they are employees of the organisation.</p>,\n",
       " <p class=\"oj-normal\">6.   Authorised representatives shall have permanently and continuously at their disposal at least one person responsible for regulatory compliance who possesses the requisite expertise regarding the regulatory requirements for medical devices in the Union. The requisite expertise shall be demonstrated by either of the following qualifications:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">a diploma, certificate or other evidence of formal qualification, awarded on completion of a university degree or of a course of study recognised as equivalent by the Member State concerned, in law, medicine, pharmacy, engineering or another relevant scientific discipline, and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">a diploma, certificate or other evidence of formal qualification, awarded on completion of a university degree or of a course of study recognised as equivalent by the Member State concerned, in law, medicine, pharmacy, engineering or another relevant scientific discipline, and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">four years of professional experience in regulatory affairs or in quality management systems relating to medical devices.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">four years of professional experience in regulatory affairs or in quality management systems relating to medical devices.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e2949-1-1\">Article 16</p>,\n",
       " <p class=\"oj-sti-art\">Cases in which obligations of manufacturers apply to importers, distributors or other persons</p>,\n",
       " <p class=\"oj-normal\">1.   A distributor, importer or other natural or legal person shall assume the obligations incumbent on manufacturers if it does any of the following:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">makes available on the market a device under its name, registered trade name or registered trade mark, except in cases where a distributor or importer enters into an agreement with a manufacturer whereby the manufacturer is identified as such on the label and is responsible for meeting the requirements placed on manufacturers in this Regulation;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">makes available on the market a device under its name, registered trade name or registered trade mark, except in cases where a distributor or importer enters into an agreement with a manufacturer whereby the manufacturer is identified as such on the label and is responsible for meeting the requirements placed on manufacturers in this Regulation;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">changes the intended purpose of a device already placed on the market or put into service;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">changes the intended purpose of a device already placed on the market or put into service;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(c)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">modifies a device already placed on the market or put into service in such a way that compliance with the applicable requirements may be affected.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(c)</p>,\n",
       " <p class=\"oj-normal\">modifies a device already placed on the market or put into service in such a way that compliance with the applicable requirements may be affected.</p>,\n",
       " <p class=\"oj-normal\">The first subparagraph shall not apply to any person who, while not considered a manufacturer as defined in point (30) of Article 2, assembles or adapts for an individual patient a device already on the market without changing its intended purpose.</p>,\n",
       " <p class=\"oj-normal\">2.   For the purposes of point (c) of paragraph 1, the following shall not be considered to be a modification of a device that could affect its compliance with the applicable requirements:</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(a)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">provision, including translation, of the information supplied by the manufacturer, in accordance with Section 23 of Annex I, relating to a device already placed on the market and of further information which is necessary in order to market the device in the relevant Member State;</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(a)</p>,\n",
       " <p class=\"oj-normal\">provision, including translation, of the information supplied by the manufacturer, in accordance with Section 23 of Annex I, relating to a device already placed on the market and of further information which is necessary in order to market the device in the relevant Member State;</p>,\n",
       " <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\n",
       " <colgroup><col width=\"4%\"/>\n",
       " <col width=\"96%\"/>\n",
       " </colgroup><tbody>\n",
       " <tr>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">(b)</p>\n",
       " </td>\n",
       " <td valign=\"top\">\n",
       " <p class=\"oj-normal\">changes to the outer packaging of a device already placed on the market, including a change of pack size, if the repackaging is necessary in order to market the device in the relevant Member State and if it is carried out in such conditions that the original condition of the device cannot be affected by it. In the case of devices placed on the market in sterile condition, it shall be presumed that the original condition of the device is adversely affected if the packaging that is necessary for maintaining the sterile condition is opened, damaged or otherwise negatively affected by the repackaging.</p>\n",
       " </td>\n",
       " </tr>\n",
       " </tbody>\n",
       " </table>,\n",
       " <p class=\"oj-normal\">(b)</p>,\n",
       " <p class=\"oj-normal\">changes to the outer packaging of a device already placed on the market, including a change of pack size, if the repackaging is necessary in order to market the device in the relevant Member State and if it is carried out in such conditions that the original condition of the device cannot be affected by it. In the case of devices placed on the market in sterile condition, it shall be presumed that the original condition of the device is adversely affected if the packaging that is necessary for maintaining the sterile condition is opened, damaged or otherwise negatively affected by the repackaging.</p>,\n",
       " <p class=\"oj-normal\">3.   A distributor or importer that carries out any of the activities mentioned in points (a) and (b) of paragraph 2 shall indicate on the device or, where that is impracticable, on its packaging or in a document accompanying the device, the activity carried out together with its name, registered trade name or registered trade mark, registered place of business and the address at which it can be contacted, so that its location can be established.</p>,\n",
       " <p class=\"oj-normal\">Distributors and importers shall ensure that they have in place a quality management system that includes procedures which ensure that the translation of information is accurate and up-to-date, and that the activities mentioned in points (a) and (b) of paragraph 2 are performed by a means and under conditions that preserve the original condition of the device and that the packaging of the repackaged device is not defective, of poor quality or untidy. The quality management system shall cover, <span class=\"oj-italic\">inter alia</span>, procedures ensuring that the distributor or importer is informed of any corrective action taken by the manufacturer in relation to the device in question in order to respond to safety issues or to bring it into conformity with this Regulation.</p>,\n",
       " <p class=\"oj-normal\">4.   At least 28 days prior to making the relabelled or repackaged device available on the market, distributors or importers carrying out any of the activities mentioned in points (a) and (b) of paragraph 2 shall inform the manufacturer and the competent authority of the Member State in which they plan to make the device available of the intention to make the relabelled or repackaged device available and, upon request, shall provide the manufacturer and the competent authority with a sample or mock-up of the relabelled or repackaged device, including any translated label and instructions for use. Within the same period of 28 days, the distributor or importer shall submit to the competent authority a certificate, issued by a notified body designated for the type of devices that are subject to activities mentioned in points (a) and (b) of paragraph 2, attesting that the quality management system of the distributer or importer complies with the requirements laid down in paragraph 3.</p>,\n",
       " <p class=\"oj-ti-art\" id=\"d1e3015-1-1\">Article 17</p>,\n",
       " <p class=\"oj-sti-art\">Single-use devices and their reprocessing</p>,\n",
       " <p class=\"oj-normal\">1.   Reprocessing and further use of single-use devices may only take place where permitted by national law and only in accordance with this Article.</p>,\n",
       " <p class=\"oj-normal\">2.   Any natural or legal person who reprocesses a single-use device to make it suitable for further use within the Union shall be considered to be the manufacturer of the reprocessed device and shall assume the obligations incumbent on manufacturers laid down in this Regulation, which include obligations relating to the traceability of the reprocessed device in accordance with Chapter III of this Regulation. The reprocessor of the device shall be considered to be a producer for the purpose of Article 3(1) of Directive 85/374/EEC.</p>,\n",
       " <p class=\"oj-normal\">3.   By way of derogation from paragraph 2, as regards single-use devices that are reprocessed and used within a health institution, Member States may decide not to apply all of the rules relating to manufacturers' obligations laid down in this Regulation provided that they ensure that:</p>,\n",
       " ...]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "blocks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "53132ed8",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "crss_mvp",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
